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Introduction and outline of this thesis
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INTRODUCTION
Trauma is a major public health problem worldwide, ranking as the fourth leading cause 
of death. Approximately 5 million people die each year as a result from injuries worldwide 
(1-3). Injuries account for 9% of global mortality. For every trauma death it is estimated 
that there are dozens of hospitalizations, hundreds of emergency department visits and 
thousands of doctor’s appointments (2). The total number of deaths from injuries was 
greater than the number of deaths from HIV/AIDS, tuberculosis, and malaria combined 
(3.8 million) (4, 5) (Figure 1). According to the World Health Organization (WHO), nearly 
one third are the result of violence (suicide, homicide and war) and nearly one quarter 
are the result of road traffic crashes. Motor vehicle collisions were the ninth leading 
cause of death in 2004 with 1.3 million deaths annually and will rise to the fifth leading 
cause of death worldwide by 2030 (2). Trauma accounts for approximately 30% of all 
Intensive Care Unit admissions (6). The burden of disease related to injuries, particularly 
road traffic injuries, interpersonal violence, war and self-inflicted injuries is expected to 
rise substantially by the year 2020 (7). 
Donald Trunkey suggested that mortality from trauma follows a trimodal distribution 
(Figure 2) (8). The first peak of “immediate deaths” is caused by devastating injury to 
the brain, brain stem, upper spinal cord, the heart or one of the major blood vessels. 
These patients usually die at the scene of injury. The second peak, characterized 
as “early deaths” represents people who die within the first few hours after an injury 
most frequently as a result of exsanguination. These first few hours have been termed 
“the golden hour” (9). Most of these injuries can now be treated and modern trauma 
programs, such as Advanced Trauma Life Support (ATLS) from the American College of 
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Figure 1. The magnitude and causes of injury mortality.  
Reprinted with permission from the World Health Organization. 
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Surgeons (ACS) and Definitive Surgical Trauma Course (DSTC) from the International 
Association for Trauma Surgery and Intensive Care (IATSIC), as well as specialized trauma 
hospitals have made an substantial impact on cognitive and clinical skills of doctors 
involved in the field of trauma and emergency care (10). The third peak, characterized as 
“late deaths” represents patients who die in days or weeks following the original trauma 
as a result of infection, sepsis or multiple organ failure (8). Trunkey stated that in this 
phase time is less of a factor than the quality of medical care and the extent of medical 
knowledge. And indeed the existence of this third peak has now been questioned by 
a number of authors claiming that progress in the field of Intensive Care Medicine has 
improved the treatment of multiple organ failure (11-13). 
The prevalence of multiple organ failure in trauma patients is around 5% (14). Mortal-
ity in multiple organ failure increases with the number of organ systems affected with 
32% mortality with two organ systems, 67% with three organ systems, and 90% mortal-
ity when four organ systems failed (14). Infectious posttraumatic complications such 
as sepsis and multiple organ dysfunction syndrome (MODS) remain important causes 
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Figure 2. The original illustration of Donald D. Trunkey from Scientific American (1983) depicting the 
suggested trimodal distribution of trauma deaths based on a sample of 862 trauma deaths recorded over a 
two year period by Trunkey’s group at San Francisco General Hospital (reprinted with permission from Scientific 
American). 
Figure 2. The original illustration of Donald D. Trunkey from Scientific American (1983) depicting the sug-
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for morbidity and mortality in patients who survive the initial trauma (15, 16). These 
complications increase the burden of trauma treatment cost to society.
In The Netherlands in 2012 more than 75000 injured patients were admitted to a 
hospital (with a mean Injury Severity Score of 9) of which around 4500 were directly 
admitted to an Intensive Care Unit (ICU). A total of 4870 patients with ISS greater than 
15 were admitted to Dutch hospitals (17).
GENETIC VARIATION AND ThE INFLUENCE ON DISEASE OUTCOME
The outcome of severe injury is determined by multiple factors. Age, co-morbidities 
and injury severity are well known factors but the genetic composition of the patient 
may well be one such factor (18-21). Genetic variations in the innate immune system of 
severely injured patients influence complement activation and the immune response by 
altered or absent protein synthesis and hence contribute to susceptibility and severity 
of infections and lead to prolonged hospital stay and increased cost. Genetic variability 
in pro- and anti-inflammatory cytokines may contribute to different clinical phenotypes 
in patients at high risk of critical illness (22). For example, variation in TLR4, a gene that 
codes for Toll-like Receptor 4 protein, may lead to prolonged stay at an ICU ward in pa-
tients with severe sepsis (23). Genetic variation in the innate immune system has been 
shown to be of importance in viral (24), bacterial (25), fungal (26) and protozoan (27) 
infections. There is increasing evidence for the role of genetic variation in the innate 
immune system on infectious complications in sepsis and trauma (18, 28-32). 
SINGLE NUCLEOTIDE POLYMORPhISMS
Humans have 23 pairs of chromosomes and, on average, all humans are 99.9% similar 
to any other human in terms of DNA sequence. The remaining 0.1% accounts for all the 
differences between humans. These physical differences are known as ‘polymorphisms’. 
The average number of nucleotide differences between a randomly chosen pair of 
humans is consistently estimated to lie between 1 in 1,000 and 1 in 1,500 (33, 34). This 
proportion is low compared with those of many other species, from fruit flies to chim-
panzees, reflecting the recent origin of our species from a small founding population 
of approximately 10.000 individuals as recent as 200,000 years (35). The coding regions 
of DNA contain the approximately 20,000-25,000 human protein-coding genes respon-
sible for the more than 20,000 known proteins (36). The coding regions - the exons are 
collectively referred to as the exome -  take up less than 2% of all DNA. More than 98% 
of the human genome is composed of non-coding DNA (ncDNA) of which the function 
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is partly unknown. Human diploid cells contain around six billion base pairs. These base 
pairs are pairs of nucleotides, the building blocks of DNA (A, C, T, and G).
Single Nucleotide Polymorphisms (SNPs; pronounced ‘snip’, plural ‘snips’) are variations 
of only one such nucleotide in the sequence of DNA. A typical genome differs from the 
reference human genome at 4.1 million to 5.0 million sites (37). More than 99,9% of 
all DNA variation is caused by SNPs and short indels making them the most common 
type of sequence variation but structural variants affect more bases affecting a total 
of 20 million base pairs in total (37). Most SNPs occur in non-coding regions of DNA. 
Because there are approximately three billion nucleotide base pairs in the haploid hu-
man genome, each pair of humans differs, on average, by two to three million base pairs.
SNPs in coding regions of DNA may have the potential to alter the amino acid sequence 
in a protein but as a result of degeneracy this is not always the case. Some proteins are 
coded by more than one codon. SNPs in coding regions are called synonymous if they do 
not affect the amino acid sequence and non-synonymous if they do influence the amino 
acid sequence of a protein. The non-synonymous SNPs can be divided into missense 
SNPs and nonsense SNPs. 
Missense SNPs result in the transcription of a different amino-acid, changing the func-
tionality of the resulting protein as is the case in Factor V Leiden thrombophilia (38) and 
sickle cell disease (39). A nonsense SNP results in the formation of a premature stopcodon 
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leading to a truncated, incomplete protein as is the case in β-thalassemia in Sardinia (40) 
and some forms of cystic fibrosis (41).
AIM AND OUTLINE OF ThIS ThESIS
This thesis aims to study the influence of sequence variations in the innate immune 
system on infectious outcome in a heterogeneous cohort of severely injured patients in 
a level 1 trauma center. 
In Chapter 1 the subject of late infectious complications following severe injury is 
introduced hypothesizing a role for genomic sequence variations in the development of 
such complications. A patient is presented in Chapter 2 who survived the initial trauma 
but developed serious infectious complications . Chapter 3 reviews all currently avail-
able literature that specifically describes the influence of different sequence variations 
on infectious complications in cohorts of trauma patients. Genetics of MBL2, a coding 
gene for a key protein in the innate immune system, is described in Chapter 4 and 
Chapter 5 describes epidemiology, evolutionary biology and the clinical effects of varia-
tions in MBL2 on various micro-organisms and clinical conditions. Chapter 6 describes 
the effects of sequence variations in MBL2, MASP2 and FCN2, important genes in the 
Lectin Pathway of complement activation, in a prospectively analyzed cohort of trauma 
patients. In Chapter 7 this same cohort is studied for effects on outcome of sequence 
variations in TLR2, TLR4, TLR9 and CD14. A prediction model is suggested in Chapter 
8 combining the effects of different combinations of haplotypes on clinically relevant 
conditions.
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ABSTRACT
Trauma is a major public health problem worldwide. Infectious complications, sepsis, 
and multiple organ dysfunction syndrome (MODS) remain important causes for morbid-
ity and mortality in patients who survive the initial trauma. There is increasing evidence 
for the role of genetic variation in the innate immune system on infectious complica-
tions in severe trauma patients. We describe a trauma patient with multiple infectious 
complications caused by multiple micro-organisms leading to prolonged hospital stay 
with numerous treatments. This patient had multiple single nucleotide polymorphisms 
(SNPs) in the MBL2, MASP2, FCN2 and TLR2 genes, most likely contributing to increased 
susceptibility and severity of infectious disease. 
Infectious complications in a severely injured patient 23
INTRODUCTION
We describe a trauma patient with multiple infectious complications caused by multiple 
micro-organisms leading to prolonged hospital stay with numerous treatments. This 
patient had multiple single nucleotide polymorphisms (SNPs) in the innate immune 
system, most likely contributing to increased susceptibility and severity of infectious 
disease.
SINGLE NUCLEOTIDE POLYMORPhISMS
Humans have 23 pairs of chromosomes and, on average, all humans are 99.9% similar 
to any other human in terms of DNA sequence. The remaining 0.1% account for all the 
differences between humans. These physical differences are known as ‘polymorphisms’. 
The coding regions of DNA contain the approximately 20,000 human protein-coding 
genes. The coding regions take up less than 2% of all DNA. More than 98% of the hu-
man genome is composed of non-coding DNA of which the function is partly unknown. 
Human diploid cells contain around six billion base pairs. These base pairs are pairs of 
nucleotides, the building blocks of DNA (A, C, T, and G).
Single Nucleotide Polymorphisms (SNPs; pronounced ‘snip’, plural ‘snips’) are variations 
of only one such nucleotide in the sequence of DNA. Around 90% of all DNA variation 
is caused by SNPs making them the most common type of sequence variation. To date 
more than 60 million SNPs have been discovered in the human genome. Most SNPs oc-
cur in non-coding regions of DNA.
SNPs in coding regions of DNA may have the potential to alter the amino acid sequence 
in a protein but as a result of degeneracy this is not always the case; some proteins 
are coded by more than one codon. SNPs in coding regions are called synonymous if 
they do not affect the amino acid sequence and non-synonymous if they do influence 
the amino acid sequence of a protein. The non-synonymous SNPs can be divided into 
missense SNPs and nonsense SNPs. Missense SNPs result in the transcription of a different 
amino-acid, changing the functionality of the resulting protein as is the case in Factor V 
Leiden thrombophilia (1) and sickle cell disease (2). A nonsense SNP results in the forma-
tion of a premature stopcodon leading to a truncated, incomplete protein as is the case 
in β-thalassemia in Sardinia (3) and some forms of cystic fibrosis (4).
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CASE REPORT
Patient A, a 57 year old mechanic with a medical history of occasional use of cocaine and 
of gradually worsening vision in the last five months as a result of optic nerve atrophy 
tripped over a low brick wall at work and fell about one meter on the back of his head. 
He was immediately found to be tetraplegic by the paramedics and was transferred to a 
level 1 trauma center. Clinically, the complete cord lesion was found to be on the level of 
C3 and C4. Computed tomography showed a congenital narrowing of the spinal canal at 
the level of C3 and C4 as well as an old fracture of the third thoracic vertebra (Figure 1). 
Magnetic resonance scanning showed hemorrhage in the myelum at the level of C3 and 
C4 as the reason for the tetraplegia (Figure 2). He was transferred to the Intensive Care 
Unit for ventilator support. On day 3 he developed acute respiratory distress syndrome 
(ARDS) and pneumonia in the right lower lobe, possibly as a result of aspiration, from 
which purulent sputum was removed repeatedly. The sputum grew Haemolytic Strep-
tococcus group C, Streptococcus pneumoniae, Haemophilus influenzae and Enterobacter 
cloacae for which he was treated with piperacillin/tazobactam. On day 10 a percutane-
ous tracheostomy was used and weaning was possible. On day 20 patient was no longer 
dependent on ventilator support. He spent a total of 32 days on the Intensive Care Unit 
and 76 days in the hospital before being discharged to a rehabilitation center. After three 
months he was admitted again, this time to the department of Internal Medicine, for fe-
Figure 1. Computed tomography showing congenital narrowing of the spinal canal at the level of C3 and 
C4. Also, an preexisting injury at the level of T2 and T3 can be seen.
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ver, diarrhea and productive cough. Radiology was suspect for pulmonary tuberculosis 
and Mycobacterium tuberculosis was eventually found in gastric contents. He was placed 
on tuberculostatic triple therapy. His diarrhea was explained by pseudomembranous 
colitis caused by Clostridium toxins. He was given metronidazol and was free of diar-
rhea after ten days. He developed deep venous thrombosis in the right subclavian vein 
ultimately leading to erysipelas and ulceration on the fingers from which Escherichia 
coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, Morganella morganii and Proteus 
mirabilis were cultured. The urine was positive for Klebsiella pneumoniae and Enterococ-
cus faecalis. The ulcers were treated surgically.
Because this patient participated in a scientific trial studying genetic variation in trau-
ma patients, his genome was sequenced for several single nucleotide polymorphisms 
(SNPs). Several SNPs were found (see table 1): heterozygosity in MBL2 exon 1 (i.e., AC 
genotype), heterozygosity in MBL2 promoter region Y-221X, (YX genotype) homozygos-
ity for the minor allele in MASP2 Y371D (DD genotype), heterozygosity in FCN2 T236M 
(TM genotype), heterozygosity in FCN2 A258S (AS genotype), homozygosity for the 
minor allele in TLR2 T-16934A (AA genotype), and heterozygosity in CD14 C-159T (CD 
genotype).
Figure 2. MR shows bleeding in the myelum at the level of C3 and C4 causing the complete cord syndrome.
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DISCUSSION
Mortality as a result of sepsis in the third peak of Trunkey (5) has not changed in recent 
times despite the improvements in treatments in the Intensive Care Unit leading to 
reduction in the incidence of sepsis itself (6). The onset of sepsis in trauma patients is 
of course multifactorial, but genetic variation at the level of the innate immune system 
is certainly one important contributing factor. SNPs in genes coding for important pro-
teins in the innate immune system, such as the complement system, may produce low 
serum levels of these proteins or they may leave these proteins dysfunctional. Hence, 
the immune response and cytokine response to trauma and infection is reduced leading 
to increased susceptibility and severity of infectious complications. These complications 
cause prolonged hospital stay and increase the use of antibiotics, the number of compli-
cations, and the cost of care to society.
The patient described in this study was proband in a prospective study in severely in-
jured trauma patients focusing on SNPs in the innate immune system and the influence 
on infectious complications. A number of SNPs were found in this patient (see Table 1).
In the lectin pathway of complement activation three important genes were studied: 
MBL2, MASP2, and FCN2. The MBL2 gene encodes for mannose-binding lectin (MBL), a 
protein that is secreted by the liver as part of the acute-phase response and is involved 
in innate immune defense. The ligands for MBL are expressed by a wide variety of 
microorganisms, and binding of the protein leads to opsonisation of the pathogen as 
well as activation of the complement system. Genetic variation in this gene leads to a 
dramatic decrease in circulating serum MBL. Heterozygosity for variants in exon 1 (i.e., 
an A0 genotype) conferred an increased risk for wound colonization and infection in 
severely injured patients (7). This had previously only been demonstrated in a murine 
model of burns (8). Also, the YX promoter genotype increased the risk of fungal coloni-
zation and infection in trauma patients (7). Presented patient carried an AC genotype 
Table 1. Genotypes found in presented patient
Gene SNP OMIM Cytogenic
 location
dbSNP ID Genotype of 
our patient
MBL2 exon 1 p.Gly57Glu 154545 10q21 rs1800451 AC
MBL2 promoter p.Y-221X 154545 10q21 rs7096206 YX
MASP2 p.Y371D 605102 1p36 rs12711521 DD
FCN2 p.A258S 601624 9q34 rs7851696 AS
TLR2 g.T-16934A 603028 4q31 rs4696480 AA
SNP: single nucleotide polymorphism. OMIM: Online Mendelian Inheritance in Man, an online catalog of 
human genes and genetic disorders. dbSNP ID: Single Nucleotide Polymorphism Database, a free public 
archive for genetic variation hosted by the National Center for Biotechnology Information (NCBI).
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in exon 1 and an YX genotype in the promoter region. MBL activates the complement 
pathway through mannan-binding lectin serine protease 2 (MASP2). MASP2 Y371D DD 
homozygosity significantly increased the risk for SIRS and septic shock in trauma pa-
tients (7). Moreover, a trend was noted for an increased risk of Gram-positive infections 
in patients with MASP2 Y371D DD genotype. Above presented patient carried the MASP2 
Y371D DD genotype. FCN2 encodes for Ficolin-2, previously termed L-ficolin, a protein 
which is mainly produced in the liver and has been shown to have carbohydrate binding 
and opsonic properties in the innate immune system. The homozygous FCN2 A258S AS 
genotype increased the risk for developing septic shock in trauma patients (7). Also, 
wound colonization and infection were significantly increased. A trend was noted for 
Gram-negative infections. The patient presented in this article carried the FCN2 A258S 
AS genotype.
Deficiencies in the lectin pathway have been linked to susceptibility of various 
pathogens, for example MASP deficient mice are highly susceptible to Streptococcus 
pneumoniae (9) and also children (10) and adults (11) have previously been shown to 
be highly susceptible to S. pneumoniae with deficiencies in MBL and MASP2. In children 
lectin pathway deficiencies may play a role in Haemophilus influenzae (12) but this was 
not found in a cohort of adults with community acquired pneumonia (13). The effect of 
MBL genotype on the susceptibility to Mycobacterium tuberculosis is controversial (14, 
15). In burn injury patients (8) and cystic fibrosis patients (16) MBL deficiency plays an 
important role on susceptibility to Pseudomonas aeruginosa infection and colonization. 
The FCN2 A258S polymorphism was previously shown to influence susceptibility to lep-
rosy (17), influence colonization with Pseudomonas aeruginosa in cystic fibrosis patients 
(16) and influence renal transplant outcome (18).
As a membrane surface receptor, TLR-2 recognizes many bacterial,  fungal, viral, and 
certain  endogenous  substances. The TLR2 T-16934A polymorphism was previously 
linked to spontaneous bacterial peritonitis in liver cirrhosis patients (19), atopic dermati-
tis, asthma and wheezing (20-22) and sarcoidosis (23). The TLR2 T-16934A genotype was 
studied in a trauma population by one author (24) who found that the TLR2 T-16934A TA 
genotype increased the risk of a Gram-positive infection and SIRS. The TLR2 T-16934A AA 
genotype seemed to protect against urinary infection, oddly. However, patient A carried 
the TLR2 T-16934A AA genotype but developed positive urine cultures.
Infectious complications are multifactorial in origin. SNPs in the innate immune sys-
tem contribute to susceptibility and severity of these infections and lead to prolonged 
hospital stay and increased cost. The presented patient demonstrates the clinical course 
of such complications that will be recognized by all surgeons and physicians. In the 
future we expect that initial genotyping will become routine workup (e.g. with DNA 
micro array chips) in all trauma patients to quantify the individual risk for developing 
infections and other complications. Patients identified to be at risk for developing infec-
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tious complications can be prophylactically treated with antibiotics in an early stage or 
can be supplemented with plasma from mixed donors containing the deficient proteins. 
Substitution therapy with purified or recombinant proteins has also produced clinical 
results, for example in the case of MBL-deficiency (25-29). Further studies are needed in 
order to determine which genes affect this risk and to quantify their effect.
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ABSTRACT
Objective: Infectious complications, sepsis and multiple organ dysfunction syndrome 
(MODS) remain important causes for morbidity and mortality in patients who survive 
the initial trauma. Increasing evidence suggests that genetic variants, particularly Single 
Nucleotide Polymorphisms (SNPs), are critical determinants for interindividual differ-
ences in both inflammatory responses and clinical outcome in sepsis patients. Although 
the effect of SNPs on sepsis and MODS has been studied in many populations and 
diseases this review aimed to summarize the current knowledge on the effect of SNPs 
on infectious complication specifically in trauma patients.
Methods: review of available literature in PubMed database.
Results: The following genes have been studied in populations of trauma patients: 
CD14, HMGB1, IFNG, IL1A, IL1B, IL1RN, IL4, IL6, IL8, IL10, IL17F, IL18, MBL2, MASP2, FCN2, 
TLR1, TLR2, TLR4, TLR9, TNF, LTA, GR, MYLK, NLRP3, PRDX6, RAGE, HSPA1B, HSPA1L, HSP90, 
SERPINE1, IRAK1, IRAK3, VEGFA, LY96, ANGPT2, LBP, MicroRNA and mtDNA. In this review 
we discuss the genes of the Pattern Recognition Receptors (PRR), Signal Transducing 
Adaptor Proteins (STAP) and Inflammatory Cytokines of the innate immune system.
Conclusions: A number of genetic variations have so far been studied in cohorts of 
trauma patients. Studies are often unique and numbers sometimes small. No definitive 
conclusions can be reached at this time about the influence of specific sequence varia-
tions on outcome in trauma patients.
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INTRODUCTION
Trauma is a major public health problem worldwide, ranking as the fourth leading cause 
of death. In 2010, there were 5.1 million deaths from injuries and the total number of 
deaths from injuries was greater than the number of deaths from HIV/AIDS, tuberculosis 
and malaria combined (3.8 million) (1, 2). Infectious complications, sepsis and multiple 
organ dysfunction syndrome (MODS) remain important causes for morbidity and mor-
tality in patients who survive the initial trauma (3). Although the rate of MODS in trauma 
patients has diminished over the last decade, MODS-related mortality, intensive care 
unit stay, and mechanical ventilation duration have not changed significantly (4, 5). 
These complications increase the burden of cost to society.
The primary inflammatory insult determines the magnitude of systemic inflammation 
and subsequent immune exhaustion, which makes patients prone for septic complica-
tions. Both a proinflammatory and anti-inflammatory response appear to coexist in 
trauma patients, possibly leading to both additional tissue damage by the immune 
system as well as increased susceptibility for subsequent infections (6). The develop-
ment of the systemic inflammatory response (SIRS) with liberation of proinflammatory 
cytokines is recognized as a part of the physiologic response to trauma. Tissue injury 
following trauma results in depressed cell-mediated immunity (especially T-cell) leading 
to an increased risk of infectious complications (7). Cytokine production varies between 
individuals, due to genetic background and certain allelic variants of cytokine genes; 
in particular, single nucleotide polymorphisms (SNPs) in coding regions of cytokine 
genes are associated with higher or lower cytokine production. Polymorphism may be 
considered as an important genetic risk factor for susceptibility to posttraumatic sepsis 
and a potential target for immunotherapy. Increasing evidence suggests that genetic 
variants, particularly SNPs, are critical determinants for interindividual differences in 
both inflammatory responses and clinical outcome in sepsis patients (8). Although the 
effect of SNPs on sepsis and MODS has been studied in many populations and diseases 
this review aims to summarize the current knowledge on SNPs in genes of the innate 
immune system in trauma patients only. 
A literature search was performed in PubMed by using “genetic variation”, “trauma”, 
and “innate immunity” and synonyms as search string. The search was finalized by cross-
checking references. Studies describing the effect of SNPs in innate immune response 
genes on infectious complications in trauma patients were included. An overview of the 
SNPs included is shown in Supplemental Table S1.
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1. PATTERN RECOGNITION RECEPTORS AND COMPLEXES
1.1 Toll-Like Receptors and associated genes
Toll-Like Receptor 1 (TLR1)
Three SNPs in TLR1 were studied in trauma patients (Table 1) (9). The TLR1 -7202G al-
lele (rs5743551) and the TLR1 742AG(p.Asn248Ser) (rs4833095) were associated with 
increased risk of mortality in sepsis and Gram-positive sepsis, respectively.
Toll-Like Receptor 2 (TLR2)
Five SNPs in TLR2 have been studied in a trauma population (Table 1).
The TLR2 19216T>C (rs3804099) CC genotype conferred a significantly higher risk of 
developing sepsis and higher MOD scores than those with a TT or TC genotype (10).
The TLR2 p.R753Q SNP was studied by two authors (11, 12). McDaniel et al. found the 
AG genotype significantly more often in septic patients (62,5%) than in aseptic patients 
(25%) in African-American patients (not so in whites) (12). Bronkhorst et al. found no 
association with sepsis or mortality in a mixed ethnic cohort of 219 trauma patients (11).
For the TLR2 -16934T>A the TA genotype increased the risk of a Gram-positive infec-
tion and SIRS in a trauma population by (11) .
Toll-Like Receptor 4 (TLR4)
SNPs in TLR4 have been studied in trauma patients (11-15) and in burns patients (16-19) 
(Table 1). In trauma patients multiple SNPs in TLR4 have been studied making compari-
son difficult (11-15).
The TLR4 896A>G (rs 4986790) was studied in four cohorts of burns patients. Three 
studies that used the same growing cohort used sepsis as endpoint (16, 17, 19) and two 
studies used mortality as endpoint (18, 19)cThe TLR4 896A>G was significantly associ-
ated with an increased risk for severe sepsis (16, 17). Shalhub could not confirm this (19). 
Moreover, no association with mortality was found (18, 19). Carriage of the TLR4 896G 
allele was associated with a decreased risk of complicated sepsis in trauma (15). The 
cosegregating TLR4 p.D299G and TLR4 p.T399I were studied in trauma patients by two 
authors (11, 12), both of whom were not able to demonstrate an association between 
genotype and infection or outcome of sepsis. Chen et al. studied the clinical relevance 
of five single nucleotide polymorphisms in TLR4 (-2381A>G, -2242T>C, -1892G>A, 
-1837A>G, and -1418T>C) in patients with major trauma (13). Only in TLR4 -2242T>C 
polymorphism higher sepsis morbidity rates and multiple organ dysfunction scores 
were found. Duan et al. prospectively studied the TLR4 11367G>C polymorphism in 
patients with major trauma (14). Patients with the C variant allele had significantly lower 
sepsis morbidity than those homozygous for the G allele. In addition, MOD scores in the 
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patients with trauma who carry the C allele were also significantly lower than those in 
the patients carrying the G allele.
Toll-Like Receptor 9 (TLR9)
Several SNPs in TLR9 have been studied in trauma patients by two authors (Table 1) (11, 
20).
Chen et al. studied the effect of five polymorphisms in TLR9 in 557 consecutive Han 
Chinese patients with severe multiple blunt trauma injuries (20). Median ISS was 25 and 
37.9% of patients developed sepsis. The rs187084  (−1486A>G), rs352140 (2848C>T) 
and rs352162 (6577T>C) SNPs were significantly associated with TLR9-mediated TNF-α 
production. Patients with a minor allele of the rs187084, rs352139 or rs352162 poly-
morphism had a higher sepsis morbidity rate. Of these three SNPs, only the rs352162 
polymorphism was significantly associated with MOD score, showing a recessive effect.
Bronkhorst et al. studied TLR9 (-1486T>C and -1237T>C) in a cohort of 219 severely 
injured patients and found -1486T>C to cause a trend toward reduced prevalence of 
Gram-positive bacteria and fungi for this SNP (p = 0.060), but no significant association 
with SIRS, sepsis, or septic shock (11).
Cluster of Differentiation 14 (CD14)
The effects of CD14 -159C>T promoter SNP were studied in burns patients (16-19, 21-23) 
and in severely injured trauma patients (11, 24-26) in Chinese (22-24, 26) and mixed 
ethnic populations (Table 1) (11, 16-19, 21, 25). Comparison of results is complicated by 
the fact that different outcome parameters were used, including wound cultures, SIRS, 
sepsis, severe sepsis, MODS and mortality. Sepsis and MODS occurred more frequently 
in both burns and trauma patients with variant genotype in some reports (17, 22-24, 
26) but was not influenced by genotype in other reports (11, 16, 19, 25). Remarkably, 
in some studies sepsis was associated with the C-allele whereas in other studies sepsis 
was associated with the T-allele (17,22). One can only speculate about the origin of this 
contrast which may be explained by differences in ethnicity of the study population. 
Mortality risk was increased by CD14 -159C variant genotype in burns patients (18, 21) 
but this effect was not found in another study (19). Differences in total body surface area 
(TBSA) of burns as well as ethnic demographic baseline characteristics may contribute 
to these opposing findings.
The effects of CD14 -1145G>A in trauma patients were studied in Chinese trauma 
patients (24, 26). In both studies, with a total of 211 trauma patients, the -1145G allele 
conferred an increased risk of sepsis and MODS.
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Myeloid differentiation-2/ Lymphocyte antigen 96 (LY96)
Zeng et al. studied 726 unrelated Han Chinese patients with major trauma for MD2 
(27). A total of 37 SNPs were identified in MD2. Thirty five of them constructed three 
haplotype blocks. Sepsis developed in around 40% of patients. Only the rs11465996 was 
shown to be significantly associated with the risk of development of sepsis and MODS in 
major trauma patients. Patients carrying the variant G allele revealed significantly higher 
sepsis morbidity rate and MOD scores.
Gu et al. studied MD2 -1625C>G in 105 severely injured patients of whom 40% de-
veloped sepsis (28). The MODS scores in trauma patients carrying G allele at position 
-1625 were significantly higher than those carrying C allele. Moreover, trauma patients 
carrying G allele appeared to have higher risk of sepsis compared to those carrying C 
allele. Sepsis morbidity was significantly different between subject with C and G alleles.
Lipopolysaccharide Binding Protein (LBP)
Zeng et al. used haplotype tagging to study SNPs in LBP in two independent cohorts 
of major trauma patients recruited from southwest and eastern China (29). Of the nine 
known SNPs in LBP only the rs2232618 (p.F436L) was significantly associated with 
higher susceptibility to sepsis and MOD. Patients carrying the variant C allele revealed 
significantly higher sepsis morbidity rate and MOD scores when compared to patients 
carrying the T allele.
1.2 Lectin Pathway Proteins
Mannose-Binding Lectin (MBL2)
Heterozygosity for the variants in exon 1 (A/0) conferred an increased risk of wound 
colonization and infection in severely injured patients (30). This had previously only 
been demonstrated in a murine model of burns (31). Also, the YX promoter genotype 
increased the risk of fungal colonization and infection in trauma patients (30).
MBL-Associated Serine-Protease 2 (MASP2)
MASP2 p.Y371D DD homozygosity increased the risk of SIRS and septic shock in trauma 
patients significantly (30). Moreover, a trend was noted for an increased risk of Gram-
positive infections in patients with DD genotype. For the MASP2 p.D120G genotype 
polymorphism no statistically significant differences were found for all endpoints al-
though, strikingly, fungi, positive blood cultures and septic shock were only found in DD 
patients (22.2%, 15.5%, and 17.9%, respectively). Another striking, yet non-significant, 
finding was that only 8.3% of DG patients developed sepsis versus 37.7% in DD patients 
(p=0.060).
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Ficolin 2 (FCN2)
The homozygous FCN2 p.A258S AS genotype increased the risk of developing septic 
shock in trauma patients (30). Also, wound colonization and infection risks were signifi-
cantly increased. A trend was noted for Gram-negative infections. 
No significant associations between the FCN2 p.T236M genotype and infectious 
events were found. Positive blood cultures developed in 25.0% of patients with a variant 
MM genotype, versus only 11.3% of patients with the common TT genotype but this 
difference was not statistically significant in a multivariate model.
1.3 Other Receptors 
Receptor for Advanced Glycation Endproducts (RAGE)
A total of 728 unrelated patients with major trauma was studied by Zeng et al. and 
genotyped for RAGE (32). Sepsis occurred in around 40% of patients with median time 
between trauma to sepsis being 6 days. From different genetic variants selected in this 
study, only the RAGE -429T>C (rs1800625) was shown to be significantly associated with 
the risk of development of sepsis and MODS in major trauma patients. The patients car-
rying the variant C allele revealed a significantly lower sepsis morbidity rate and MOD 
scores, when compared with those carrying the T allele. Moreover, in vitro LPS-induced 
TNF-α production was significantly lower in patients with the variant C allele than in 
those with wild T allele.
NOD-like Receptor Family, Pyrin Domain Containing 3 (NLRP3)
Zhang studied six SNPs in the NLRP3 gene of 718 Chinese patients with major blunt 
trauma with a mean ISS of 22.5 (33). 40% of patients developed sepsis with a mean 
time to sepsis of 7 days. The NLRP3 -1017G>A polymorphism (rs2027432), although it 
was found in only three patients with AA variant homozygotes in this study cohort, 
was significantly associated with higher risk of MODS. In addition, the NLRP3 5134A>G 
(rs12048215) polymorphism was significantly associated with a lower sepsis morbidity 
rate, showing 26.4% in GG versus 44% in AA. Data from multiple logistic regression 
analyses further indicated that the patients with the rs12048215 polymorphism had a 
lower risk of developing sepsis after adjusting for possible confounders. The rs2027432 
polymorphism was significantly associated with higher IL-1β levels.
Glucocorticoid Receptor (GR)
Duan et al. studied a cohort of 95 severe trauma patients with a mean ISS of 27 (34). It 
appeared that the BclI mutation in the GR gene was not associated with posttraumatic 
sepsis or organ dysfunction.
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2. SIGNAL TRANSDUCING ADAPTOR PROTEINS
Interleukin-1 Receptor-Associated Kinase 1 (IRAK1)
Sperry et al. studied a cohort of 321 patients with a median ISS of 16 for the T>C substitu-
tion (rs1059703) at position 1595 in exon 12 of IRAK1 which results in a non-synonymous 
mutation (p.L532S) (35). They found this SNP to be a very strong independent predictor 
of post-trauma multiple organ failure and mortality
Interleukin-1 Receptor-Associated Kinase 3 (IRAK3)
Meyer et al. genotyped 474 patients with acute lung injury (ALI) from a prospective 
critically ill trauma patients cohort study for 25 candidate genes using the IBC chip (36). 
The incidence of ALI their cohort was 30%. IRAK3 was found to be associated with ALI in 
patients from African descent.
3. INFLAMMATORY CYTOkINES
3.1 Interleukins
Interleukin-I (IL1A, IL1B, IL1RN)
IL1A
In a cohort of 308 Han Chinese trauma patients with ISS>16 the IL1A -889C>T TT geno-
type had the highest risk of sepsis and produced the lowest serum levels of Il-1α (Table 
1) (37).
IL1B
Carrying an IL1B-Taq-1 3953C>T CT genotype in combination with the IL10 -592A>C AC 
genotype predisposed to acute respiratory failure in Caucasian trauma patients (N=216; 
ISS>16) (p=0.003) (Table 1) (38).
The IL1B -1470G>C was studied in two overlapping cohorts of severely injured Han 
Chinese patients from the same hospital (37, 39). Chinese trauma patients carrying the 
major -1470G allele were more likely to develop sepsis than those with the minor -1470C 
allele in both studies.
The IL1B -511T>C (rs16944) was studied in the previously overlapping cohorts of 238 
and 308 Han Chinese patients with severe trauma (37, 39). The CC genotype conferred a 
statistically significant increase in the risk of sepsis. In a Caucasian cohort of 119 multiple 
trauma patients IL1B -511T>C variation was not found to confer any effect on sepsis (38).
The IL1B SNP most studied is the -31C>T (16-19, 21, 37, 39). In mixed-ethnic burns 
patients from the USA (TBSA>15%) this SNP seems to be no relevant risk factor for the 
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development of sepsis nor for mortality (16-19, 21). In Han Chinese multiple trauma 
patients, however, the IL1B -31C>T major CC genotype seemed to protect against sepsis 
(30.3% and 37.9%) following major trauma (37, 39).
IL1RN
In one study the effect of IL1RN variant 2 variable number tandem repeat (VNTR) poly-
morphism was studied in patients with traumatic brain injury (TBI) (Table 1) (40). IL1RN 
VNTR allele 2 carriers were more likely to have hemorrhagic events after TBI. In another 
study in severe trauma patients a IL1RN SNP 130T>C (rs315952), distinct from the well-
described VNTR SNP, was associated with decreased risk of ARDS (41).
Interleukin-4 (IL4)
Two studies from the same hospital with overlapping patient cohorts reported the influ-
ence of IL4 -589T>C genotype in a cohort of 308 Chinese severe trauma patients with 
a mean ISS of 25.5 (Table 1) (37, 42). A total of 48.4% of patients developed sepsis. The 
frequency of the TC heterozygous genotype in the sepsis group (37.6%) was significantly 
higher than in nonsepsis group (25.2%). There was a significant influence of the minor 
C allele. No relationship was observed between IL4 -589T>C and MODS in these major 
trauma patients.
Interleukin-6 (IL6)
The IL6 -174G>C (rs1800795) was studied in three cohorts of burns patients (16-19, 
43), six cohorts of trauma patients (12, 38, 44-47) and a cohort of traumatic brain injury 
(TBI) patients (Table 1) (48). Only two out of these articles described an increased risk 
of sepsis with presence of the minor -174C allele (17, 45). In a cohort of TBI patients 
the GG genotype was found significantly more frequently in the survivor group than in 
non-surviving patients (48).
Chinese trauma patients carrying the IL6 -572G>C CC genotype had significantly more 
sepsis morbidity than with a CG or GG genotype (37, 46). A small Bosnian cohort how-
ever failed to demonstrate any influence of this SNP (47).
Interleukin-8 (IL8)
The effect of IL8 -251A>T on the development of ARDS was studied in one cohort of 
97 blunt trauma patients of whom 23 developed ARDS (Table 1) (49). The allele and 
genotype distribution of the polymorphism in this cohort did not exhibit a significant 
association with the development of ARDS or mortality. Patients with the AA genotype 
showed a significantly longer duration of mechanical ventilation compared to patients 
with the IL8 -251TT genotype.
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Interleukin-10 (IL10)
The effects of IL10 -592A>C in trauma patients have been described in seven studies 
(Table 1) (12, 37, 38, 50-52). Three studies (12, 50, 51) found conflicting results of genetic 
variation in this gene on outcome. Schröder et al. found an increased risk for MODS in 
-592AC genotypes. Huebinger et al. found that carriage of the minor -592A allele was 
associated with a decreased risk of mortality. McDaniel et al. found that patients carrying 
the IL10 ACC/ATA low producing genotypes were at a lower risk of developing sepsis.
IL10 -819C>T was studied in five cohorts of trauma patients (12, 37, 43, 50, 52). Three 
studies describe an effect on outcome (12, 37, 50). Huebinger et al. found that the minor 
-819T allele was significantly associated with a decreased risk of mortality. McDaniel et 
al. found that patients carrying the IL10 ACC/ATA low producing genotypes were at a 
lower risk of developing sepsis. In a cohort of Chinese trauma patients (where C ap-
peared to be the minor allele) it was shown that this C allele conferred a decreased risk 
of sepsis (37).
IL10 -1082G>A was studied by ten authors (12, 36-38, 43, 51-55). Six authors observed 
effects on outcome (12, 36, 38, 52-54). McDaniel et al. (12) found that patients who car-
ried the IL10 ACC/ATA low producing genotypes were at a lower risk of developing sepsis. 
Zeng et al., however, found that patients with the major A allele had significantly higher 
risk of sepsis (52). Jin et al. (54) as well as Schroeder et al. (38) described a reduced risk 
of ARDS and acute respiratory failure in GG genotypes. In contrast, Gong et al. found the 
-1082GG genotype to be associated with an increased risk of ARDS in patients younger 
than 52 years old. 
Interleukin-17F (IL17F)
Accardo Palumbo et al. studied the effect of 7488T>C (His161Arg)(rs763780) in IL17 
in a cohort of burns patients (Table 1) (43). At the third day, burn patients had a very 
significant increase in IL-17 plasma levels. However, there were no statistically significant 
differences in IL17 genotype distributions among patients that did or did not developed 
sepsis.
Interleukin-18 (IL18)
McDaniel et al. were unable to demonstrate a significant effect of SNPs in IL18 in trauma 
patients (Table 1) (12). Stassen et al. studied IL18 -137G>C and IL18 -607C>A in 69 trauma 
patients (56). Although the individual SNPs were not associated with outcome, patients 
carrying both the -607CA genotype and a -137GC genotype (CA/GC) had a significantly 
reduced risk of sepsis. These data suggest that IL18 genetic variability may play a role in 
the predisposition for the development of postinjury sepsis.
44 Chapter 3
3.2 Other Inflammatory Cytokines
high-Mobility Group Box 1 (HMGB1)
Three HMGB1 polymorphisms -1514T>C, 2179C>G and 6850G>A were studied in a 
cohort of 556 Han Chinese patients with major trauma. A total of 39.7% of patients 
developed sepsis. The HMGB1 2179C>G variant GG genotype predisposed to the oc-
currence of sepsis (p=0.003) and MODS (P=0.011) in trauma patients (57). With respect 
to the other 2 SNPs, there were no significant differences in sepsis morbidity rates and 
MOD scores.
Interferon-γ (IFNG)
In a mixed-ethnic cohort of 68 trauma patients (ISS > 15) of whom 42–50% developed 
sepsis (12) the IFNG 841T>A AA genotype protected against sepsis in African American 
patients, whereas this was not clear for Caucasian patients. The authors suggest that the 
carriage of the AA genotype could cause faster elimination of the pathogens (12). In an 
other cohort of 308 Han Chinese trauma patients (ISS>16) the IFNG 541T>A polymor-
phism was unrelated to sepsis or MOD (37).
Tumor Necrosis Factor (TNF)
Three SNPs in TNF have been studied in trauma and burns patients by nine authors 
(Table 1) (12, 16-19, 21, 37, 58-62).
The TNF -308G>A (rs1800629) was described in burns patients by two authors in 
five studies (16-19, 21) and in trauma patients in eight studies (12, 15, 19, 37, 58-62). 
Increased risk of sepsis and of mortality has been observed by seven authors (16, 17, 19, 
37, 58, 61, 62) but was not seen by four authors (12, 15, 18, 21, 60). Moreover, Gill et al. 
demonstrated in a cohort of trauma patients that the A allele was significantly associ-
ated with the risk of microchimerism after allogenic transfusion of cells (59).
The TNF -238G>A (rs361525) was studied in trauma patients by one author (62). There 
was no influence of -238G>A variation on sepsis outcome in a cohort of 152 severely 
injured patients.
Also, the TNF -376G>A (rs1800750) was studied in trauma patients by one author (62). 
There was no influence of -238G>A variation on sepsis outcome outcome in a cohort of 
152 severely injured patients.
Lymphotoxin-α (LTA)
Effects of variation in lymfotoxin-α LTA 252A>G (rs909253) (previously known as TNF-β 
NcO1) was studied in trauma patients in five manuscripts (45, 58, 60, 61, 63). Three au-
thors observed an effect on clinical outcome (60, 61, 63) and two did not (45, 58). 
Majetschak et al. found that severe posttraumatic sepsis was significantly increased 
in patients homozygous for the allele TNFB2 (presently termed the A allele) (63). Three 
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years later, Majetschak again found that patients developing severe sepsis after trauma 
were significantly more likely to be homozygous for TNFB2 and this time also homozy-
gous for TNFB1 (presently termed the G allele) (60). Menges et al. also found that carriage 
of the G allele (TNFB1) conferred an increased risk of developing sepsis (61). Hildebrand 
et al. (45) and Duan et al. (58) found no effect on sepsis morbidity.
CONCLUSION
Severe injury or multiple trauma (the so-called ‘first hit’) evokes a systemic inflamma-
tory response in trauma patients. In uncomplicated cases this response is temporary 
and predictable to a certain extent. If the initial hit however is big enough it may 
produce a Systemic Inflammatory Response Syndrome (SIRS). The following emergency 
damage-control surgery and later definitive surgical procedures (the ‘second hit’) may 
further exhaust the immune system potentially leading to immune paralysis causing 
the Compensatory Anti-inflammatory Response Syndrome (CARS). Several mechanisms 
contribute to the development of SIRS such as hormonal, metabolic, hemodynamic, 
immunological, cell-mediated and ischemia/reperfusion processes (64).
The outcome following major trauma is thus determined by many factors of which 
sequence variation in the human genome may well be one such factor. A number of 
genes have been studied so far but these studies are generally unique and numbers are 
often small. Outcome parameters of studies, as shown in this review are sometimes dif-
ferent making pooling of results or comparison complicated. Nevertheless, some single 
nucleotide polymorphisms clearly appear to exert an effect on the outcome. 
Identifying patients at risk of developing infectious complications may improve their 
outcome by targeted treatments such as antibiotic prophylaxis, substitution therapy 
or plasma transfusions. But unfortunately too little information is currently available to 
draw firm conclusions. Further research in this field is necessary. Since systemic response 
to trauma is a complex and polygenic phenotype, more genes will have to be studied 
in larger cohorts to determine their exact influence on outcome in severely injured 
patients. State-of-the-art techniques like exome sequencing and whole genome SNP 
arrays should be used in future studies in order to identify relevant sequence variations 
in other immune response genes and signalling pathways as well.
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Supplemental Table S1. Summary of SNPs studied in populations of trauma patients
Gene OMIM Cytogenetic
Location
SNP dbSNP ID References
Pattern Recognition Receptors and Complexes
TLR1 601194 4p14 -7202A>G rs5743551 (9)
742A>G rs4833095 (9)
1804G>T rs5743618 (9)
TLR2 603028 4q31 -15607A>G rs1898830 (10)
19216T>C rs3804099 (10)
22215T/G rs7656411 (10)
p.R753Q rs5743708 (11, 12)
p.R753Q rs5743708 (11, 12)
-16934T>A rs4696480 (11)
TLR4 603030 9q33 -2381A>G rs2737190 (13)
-2242T>C rs10116253 (13)
-1892G>A rs10983755 (13)
-1837A>G rs1927914 (13)
-1418T>C rs10759932 (13)
11367G>C N.A. (14)
896A>G rs4986790 (11, 12, 15-19)
1196T>C rs4986791 (11, 12)
TLR9 605474 3p21 -1486T>C rs187084 (11, 20)
2848C>T rs352140 (20)
6577T>C rs352162 (20)
g.6808A>G rs352139
-1237T>C rs5743836 (11)
CD 14 158120 5q31 -159C>T rs2569190 (11, 16-19, 21-26)
-1145G>A rs2569191 (24, 26)
LY96 605243 8q21 -1625C>G rs11465996 (27, 28)
LBP 151990 20q11 26877T>C rs2232618 (29)
MBL2 154545 10q21 Codon 52 rs5030737 (30)
Codon 54 rs1800450 (30)
Codon 57 rs1800451 (30)
MASP2 605102 1p36 p.Y371D rs12711521 (30)
p.D120G N.A. (30)
FCN2 601624 9q34 p.A258S rs7851696 (30)
p.T236M rs17549193 (30)
RAGE 600214 6p21 -407 to -345 63bp ins/del (32)
570G>A rs2070600 (32)
-374T>A rs1800624 (32)
-429T>C rs1800625 (32)
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Supplemental Table S1. Summary of SNPs studied in populations of trauma patients (continued)
Gene OMIM Cytogenetic
Location
SNP dbSNP ID References
NLRP3 606416 1q44 -1017G>A rs2027432 (33)
5134A>G rs12048215 (33)
hGR/NR3C1 138040 5q31 Bcl I C>G rs41423247 (34)
Signal Transducing Adaptor Proteins
IRAK1 300283 Xq28 1595 T>C rs1059703 (35)
IRAK3 604459 12q14 15SNPs Ht Block 1 (36)
Inflammatory Cytokines
IL1A 147760 2q13 -889C>T rs1800587 (37)
IL1B 147720 2q13 3953C>T rs1143634 (38, 45)
-1470G>C N.A. (37, 39)
-511T>C rs16944 (37-40)
-31C>T rs1143627 (16-18, 37, 39)
IL1RN 147679 2q13 VNTR rs315952 (40)
C>T rs315952C (41)
IL4 147780 5q31 -589T>C rs2243250 (37, 42)
IL6 147620  7p15 -174G>C rs1800795
(12, 16-19, 36, 38, 43, 
44, 46-48)
-572G>C rs1800796 (37, 46, 47)
-597G>A rs1800797
IL8 146930 4q13 -251A>T rs4073 (49)
IL10 124092 1q32 -1082G>A rs1800896 (12, 36-38, 43, 51-55)
-819C>T rs1800871 (12, 37, 43, 50, 52)
-592C>A rs1800872 (12, 37, 38, 43, 50-52)
IL17F 606496 6p12 7488T>C rs763780 (43)
IL18 600953 11q23 -137G>C rs187238 (12, 56)
-607C>A rs1946518 (12, 56)
TNF 191160 6p21 -308G>A rs1800629
(12, 15-19, 21, 37, 
58-62)
-238G>A rs361525 (62)
-376G>A rs1800750 (62)
LTA 153440 6p21 252A>G rs909253 (45, 58, 60, 61, 63)
IFNG 147570 12q15 874T>A rs2430561 (12, 37)
HMGB1 163905 13q12 -1514T>C rs1412125 77
2179C>G rs2249825 (57)
6850G>A rs1045411 (57)
Other Genes not belonging to the Innate Immune System
MYLK 600922 3q21 p.P21H rs28497577 (65)
p.S147P rs9840993 (65)
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Supplemental Table S1. Summary of SNPs studied in populations of trauma patients (continued)
Gene OMIM Cytogenetic
Location
SNP dbSNP ID References
rs4678047 (65)
PRDX6 602316 1q25 43 SNPs (66)
HSPA1B 603012 6p21 1538A>G N.A. (67)
HSPA1L 140559 6p21 2437C>T rs2075800 (67)
HSP90B1 191175 12q23 -144C>A rs9472238 (68)
SERPINE1 173360 7q22 -688 rs1799768 (18, 69)
VEGFA 192240 6p21 Ht Block 1 (36)
ANGPT2 601922 8p23 127635T>A rs1868554 (70)
135709T>C rs2442598
mtDNA mtDNA T4216C (71)
MicroRNA stem-loop 37/5p +22 G>C rs4919510 (72)
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INTRODUCTION
Mannose-binding lectin (MBL), also known as mannan-binding protein (MBP), is a pro-
tein that specifically binds or crosslinks carbohydrates. Lectins are involved in comple-
ment activation via the lectin pathway. The complement system provides immediate 
defense against infection and has proinflammatory effects; it is considered part of both 
the innate and adaptive immune systems.
This topic will discuss the genetic defects and polymorphisms of the MBL2 gene and 
the function of the MBL protein. The diagnosis of MBL deficiency, diseases associated 
with both low and high levels of MBL, and other aspects of the complement system are 
discussed separately. (See “Mannose-binding lectin deficiency” and “Complement path-
ways” and “Overview and clinical assessment of the complement system” and “Regula-
tors and receptors of the complement system”.)
ThE MBL GENE
In many animals there are two mannose-binding lectin (MBL) genes, MBL1 and MBL2 
that code for a functional product. However, in humans the MBL1 gene, MBL1P1 is a 
pseudogene (ie, it does not produce a functional protein) [1]. The two MBL genes are 
most likely the result of a gene-duplication event [2].
The gene encoding functional MBL in humans, MBL2 is located on the long arm of 
chromosome 10 (10q11.2-q21) [3]. The MBL2 gene is also known as collectin subfamily 
member 2 or COLEC2 [4].
The human MBL protein is encoded by four exons. The MBL2 gene also contains an 
extra exon about 1 kb upstream of exon 1, named exon 0, which may initiate transcrip-
tion of the MBL2 gene [5]. Gene expression is primarily regulated by several consensus 
elements in the promoter region [4].
The normal allele is called allele A. To date, three point mutations have been identified, 
all in exon 1 [6-8]:
• Allele B – Codon 54, GGC to GAC (Gly_Asp)
•	 Allele C – Codon 57, GGA to GAA (Gly_Glu)
•	 Allele D – Codon 52, CGT to TGT (Arg_Cys)
The wild-type is denoted MBL2 genotype A/A and the pooled MBL variants (B, C, and 
D) are denoted MBL2 genotype 0/0 (where the “0” stands for one of the variant alleles).
The MBL variant proteins are unstable and probably have a shorter half-life in the 
circulation [9-11]. In addition, all mutations in exon 1 interfere with the formation of 
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higher order oligomers [12]. The variant MBL has a lower molecular weight and does not 
bind mannan efficiently nor activate complement. (See ‘The MBL protein’ below.)
In addition to the three mutations in exon 1, there are several other polymorphic sites 
located in the MBL promoter region that are associated with decreased MBL serum con-
centration. These include single nucleotide polymorphisms (SNPs) located at position 
-550 (H/L variant), and -221 (Y/X variant), both G to C nucleotide substitutions. Another 
polymorphic site is located at position +4 of the 5’-untranslated portion of the MBL2 
gene (P/Q variant, C to T). The promoter haplotypes, HY, LY, and LX are associated with 
high, medium, and low levels of MBL serum concentrations, respectively. In addition, 
a low producing LX haplotype in the homozygous state seems to downregulate the 
basal expression of MBL as effectively as a single structural variant [13,14]. The molecu-
lar mechanisms resulting in different MBL serum levels associated with the MBL2 gene 
promoter types have not yet been elucidated [12,13,15].
Four common haplotypes have been identified on a normal A chromosomal back-
ground: HYPA, LYPA, LYQA, and LXPA, with high, high-intermediate, intermediate, and 
low promoter activity. The variant alleles are associated with HYPD, LYPB, and LYQC 
[4,13,15]. Thus, seven common haplotypes are found. Other haplotypes have been 
described, but are rare due to linkage disequilibrium [16]. The serum level of MBL is 
strongly associated with the individual’s haplotype.
ThE MBL PROTEIN
Animal lectins that are dependent upon the presence of calcium ions are named C-type 
lectins. Members of the C-type family include selectins, hepatic type II receptors, type I 
transmembrane proteins, collectins (collagen-like lectins), and lecticans.
The collectins include three serum proteins (mannose-binding lectin, bovine conglu-
tinin, and bovine collectin 43) and two lung surfactant proteins (SP-A and SP-D) [17-19]. 
These proteins play important roles in innate immunity [20-22]. (See “An overview of the 
innate immune system”, section on ‘Collectins’.)
The mannose-binding lectin (MBL) protein consists of multimers of an identical 25 kDa 
polypeptide chain synthesized by the liver [4]. Three polypeptide chains form a triple 
helix within the collagen-like region. These structural subunits form covalent oligomers 
via disulfide bonds at the N-terminal end. MBL in serum primarily consists of trimers 
and tetramers of 9 and 12 polypeptides respectively, but the oligomers can range from 
dimers to hexamers [4]. These higher-order oligomers are necessary for the function of 
MBL and the interaction with MBL-associated serine proteases (MASPs) [23,24].
MBL binds carbohydrates in the presence of Ca2+ through the C-terminal carbohy-
drate-recognition domain (CRD) [17,18,25]. The CRD is able to form bonds with hydroxyl 
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groups on specific ligands, including mannose, N-acetyl-d-glucosamine (GlcNAc), N-
acetyl-mannosamine, fucose, and glucose. These carbohydrates are found on pathologic 
microorganisms, including bacteria, fungi, parasitic protozoans, and viruses. CRD also 
recognizes molecular structures of dying host cells, including nucleic acids, mitochon-
dria, and the metalloproteases, meprin-alpha and -beta [4,26]. Carbohydrates that are 
found on mammalian glycoproteins, such as D-galactose and sialic acid, have no affinity 
for MBL. Thus, MBL is able to bind to microbes or unwanted material and trigger the 
activation of the lectin pathway, but it avoids recognition of self.
ThE LECTIN PAThWAY
The complement system can be activated through three pathways: the classical path-
way, the alternative pathway, and the lectin pathway (figure 1). The lectin pathway has 
an activation scheme similar to that of the classical pathway, but lectins substitute for 
antibodies and an associated protease replaces C1. Mannose-binding lectin (MBL) and 
related collectins bind sugar residues on the microbial surface; their associated prote-
ases (MASPs) subsequently cleave C4 and C2. The complement activation pathways are 
discussed in greater detail separately. (See “Complement pathways”.)
MBL DEFICIENCY
Overall, individuals generally benefit from normal levels of mannose-binding lectin 
(MBL). However, in some cases low levels appear to be advantageous. The association of 
both decreased and elevated serum levels of MBL, due to different polymorphisms of the 
MBL2 gene and its promoter, with a variety of diseases is discussed in detail separately. 
(See “Mannose-binding lectin deficiency”.)
SUMMARY
• Mannose-binding lectin (MBL) is a protein involved in complement activation via 
the lectin pathway (figure 1). The complement system provides immediate defense 
against infection and has proinflammatory effects. (See ‘Introduction’ above and ‘The 
lectin pathway’ above.)
• Decreased levels of MBL can result from mutations in the MBL2 gene or its promoter. 
(See ‘The MBL gene’ above.)
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• MBL binds to carbohydrates on microbes or unwanted material and triggers the ac-
tivation of the lectin pathway, but it does not recognize self carbohydrates. (See ‘The 
MBL protein’ above and ‘The lectin pathway’ above and “Complement pathways”.)
Use of UpToDate is subject to the Subscription and License Agreement.
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INTRODUCTION
Mannose-binding lectin (MBL), also known as mannan-binding protein (MBP), is a 
protein that is involved in complement activation via the lectin pathway (figure 1). The 
complement system provides immediate defense against infection and has proinflam-
matory effects. 
Literature review current through: Nov 2015. | This topic last updated: Nov 18, 
2015. 
INTRODUCTION — Mannose-binding lectin (MBL), also known as mannan-binding 
protein (MBP), is a protein that is involved in complement activation via the lectin 
pa hway (figure 1). The l ent system provides immediate defense against 
infection and has proinflammatory effects.  
 
Figure 1. Pathways of complement activation 
Figure 1. Pathways of complement activation
MBL deficiency is defined as a serum level <500 ng/mL. It is a laboratory finding that 
does not necessarily equate to a clinical disorder. MBL deficiency is associated with a 
large and heterogeneous group of disease processes. However, subnormal levels are 
also found in healthy people. To date, there is no consensus on the clinical relevance of 
MBL deficiency or its treatment.
This topic reviews the genetics, epidemiology, diagnosis, and management of MBL 
deficiency and also reviews diseases associated with both low and high levels of MBL. 
Genetic defects and polymorphisms of the MBL2 gene, the function of the MBL protein, 
and other disorders of the complement system are discussed separately. (See “Mannose-
binding lectin” and “Inherited disorders of the complement system”and “Acquired disor-
ders of the complement system”.)
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EPIDEMIOLOGY
People with mutations of both mannose-binding lectin 2 (MBL2) alleles constitute 
between 1 and 65 percent (median 5 percent) of the population, depending upon the 
ethnic group [1,2]. Heterozygosity, or the presence of mutations in one MBL2 allele, is 
found in more than 30 percent of the population in most ethnic groups evaluated. Thus, 
up to 40 percent of most populations may have single nucleotide polymorphisms in one 
or both MBL2 alleles [3,4]. (See “Mannose-binding lectin”, section on ‘The MBL gene’.)
PAThOPhYSIOLOGY
Genetics
The normal or wild-type MBL allele is called allele A. Three point mutations have been 
identified, all in exon 1, designated alleles B, C, and D. As a group, the variant alleles are 
also called allele or genotype 0. There is an autosomal pattern of inheritance. However, 
the MBL serum phenotype is gene-dose dependent, so inheritance cannot be defined 
as dominant or recessive. The level of functional MBL is decreased by as much as 90 per-
cent, even in heterozygotes. The effect of the D allele in heterozygotes is less dramatic 
than that of the B or C alleles. (See “Mannose-binding lectin”, section on ‘The MBL gene’.)
The B variant mutation occurs at a gene frequency of approximately 25 percent in Eur-
asian populations but is virtually absent in sub-Saharan West Africa [5]. The C variant is 
absent among Asians and American Indians, is rare among Caucasians, but is commonly 
seen in sub-Saharan African populations, with a frequency of 50 to 60 percent [6]. The D 
allele occurs with lower frequency than the B or C alleles and appears to be confined to 
Caucasians and northern East African populations [7].
In addition to the three mutations in exon 1, there are several other single nucleotide 
polymorphisms (SNPs) located in the MBL2 promoter region that are associated with de-
creased MBL serum concentration (variants H/L, Y/X, and P/Q). There are many possible 
combinations of exon 1 mutations and promoter SNPs. However, only seven common 
haplotypes are found in humans:
•	 Promoter haplotypes associated with a normal (“wild-type”) exon 1 haplotype 
include HYPA, LYPA, LYQA, and LXPA, which have high, high-intermediate, intermedi-
ate, and low promoter activity, respectively.
•	 The genotype 0 variant haplotypes include HYPD, LYPB, and LYQC.
•	 The LXPA haplotype is seen in 24 percent of Caucasians and, as such, is the most 
common cause of MBL deficiency in this group (either LXPA homozygous or LXPA 
plus a variant haplotype).
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•	 LYPB is the most common variant haplotype in Asians and Caucasians (22 and 12 
percent, respectively) but is rare in Africans [8].
•	 LYQC is the haplotype most often found in Africans (24 percent) but is uncommon in 
Caucasians and Asians.
Normal homozygotes (genotype  A/A)  generally have MBL levels above 1000  ng/
mL, with levels up to 10,000 ng/mL [8,9]. Heterozygous individuals (A/0 genotype) have 
approximately one-sixth to one-eighth the normal functional level of MBL, with levels 
generally ranging from 500 to 1000 ng/mL. Individuals homozygous for variant MBL2 al-
leles (genotype 0/0) usually have levels <50 ng/mL. Similar levels are seen in patients 
with the promoter variants LXP and normal A allele (LXPA haplotype) on one gene and 
the B, C, or D allele on the other. One patient was reported with undetectable MBL 
(<20  ng/mL)  [10]. The combination of mutations in exon 1 and the promoter region 
results in a dramatic variation in MBL concentrations of up to 1000-fold in apparently 
healthy individuals.
High worldwide prevalence of MBL deficiency or low protein-producing alleles 
appears to be caused exclusively by human migration and genetic drift, indicating 
that MBL2 variation does not have a strong effect on population fitness [11]. However, 
other data suggest that MBL deficiency may have an evolutionary advantage. The diverse 
role of MBL in innate immunity, particularly its effects on infectious disease susceptibil-
ity, may have led to selection for the heterozygous states of  MBL2. There are several 
processes by which MBL heterozygosity may be advantageous in an evolutionary sense, 
including protection against adverse effects of various infectious diseases and lethal 
manifestations of atherosclerosis, a disease which now seems to have a more ancient 
history than previously assumed [12]. In addition, high MBL production (normal geno-
type A) is associated with preterm birth compared with intermediate MBL production 
(variant genotype B) and low MBL production (variant genotype C) [13].
Physiology
Circulating MBL in the newborn, measured in umbilical cord blood, is of fetal, not ma-
ternal, origin [14]. Levels in term infants are two-thirds that of their mothers and reach 
adult levels in approximately one month.
Plasma levels of MBL are stable over time in individuals [15]. No circadian variation is 
described. Physical exercise does not affect levels [16]. MBL is reported to behave like an 
acute-phase reactant, although levels increase only approximately 1.5-fold one to two 
weeks after the inciting event and show variation between individuals [17]. Persons with 
low levels of MBL do not reach serum levels of wild-type individuals during an acute-
phase response.
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CLINICAL MANIFESTATIONS
Many individuals suffer no sequelae from MBL deficiency due to different polymor-
phisms of the  MBL2  gene and its promoter because of redundancies in the immune 
system [18]. Increased susceptibility to infection is generally seen in patients with MBL 
deficiency when additional factors that compromise the immune system are present [8]. 
However, some individuals with insufficient serum MBL levels who are otherwise immu-
nocompetent are more likely to have recurrent infectious disease and poorer outcomes 
from infection. It is possible that another part of the immune system that overlaps with 
MBL is functioning at the low end of normal in these individuals, and this lower level of 
function is not sufficient to make up for the MBL deficiency [19].
The role of MBL in autoimmune disorders is less clear cut. Overall, individuals gener-
ally benefit from normal levels of MBL. However, in some cases, low levels appear to be 
advantageous [20]. This dual effect is called heterosis.
Infection
The innate immune system constitutes the principal defense against infection when the 
adaptive immune response is either immature or compromised. In certain individuals, 
deficiency of MBL is associated with an increased frequency of pyogenic infections, 
especially encapsulated bacteria, due to defective opsonization. Low levels of MBL are 
associated with increased susceptibility to and severity of certain infections. (See “An 
overview of the innate immune system”, section on ‘Collectins’.)
In immunocompromised hosts
An increased incidence of infectious disease is seen in immunocompromised individu-
als and immunologically immature neonates and infants who are also MBL deficient. 
Patients may be immunocompromised for a number of reasons, including immunologic 
immaturity, acute critical illness, chronic disease, chemotherapy, transplantation, major 
surgery, and other immunodeficiencies.
An opsonization defect has been described in infants and young children with MBL 
deficiency [19,21-25]. These patients present with recurrent upper respiratory tract infec-
tions (URIs), chronic diarrhea, and failure to thrive. Another study found an increased risk 
of acute URIs in older infants with MBL insufficiency [26]. However, the data in children 
are contradictory regarding the possible association of MBL levels with sepsis [27] and 
lower respiratory symptoms [28]. Concomitant specific antibody deficiency is common 
in children with MBL deficiency [29]. These patients have more frequent episodes of 
otitis media, pneumonia, and sepsis and are more likely to receive prophylactic antibiot-
ics  and/or  immune globulin  replacement therapy than children with MBL deficiency 
alone. (See “Specific antibody deficiency”.)
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MBL levels are inversely correlated with the frequency of lower respiratory tract in-
fections and bronchiectasis in patients with common variable immunodeficiency. MBL 
deficiency may also be found in combination with immunoglobulin G2 (IgG2) deficiency 
in infants and young children who present with recurrent infections. (See “IgG subclass 
deficiency” and “Common variable immunodeficiency in children”and “Clinical manifes-
tations, epidemiology, and diagnosis of common variable immunodeficiency in adults”.)
MBL deficiency is associated with an increased rate of infections in patients who have 
undergone solid organ [30-34] or hematopoietic cell transplantation [35] or who have 
undergone major gastrointestinal surgery for malignant disease [36]. In patients with 
cystic fibrosis, MBL deficiency is associated with earlier colonization with Pseudomonas, 
more rapid decline in lung function, and earlier death secondary to end-stage lung 
disease. (See “Cystic fibrosis: Genetics and pathogenesis”.)
The effect of MBL deficiency in critically ill patients or in those receiving chemotherapy 
is variable. A meta-analysis of studies of critically ill patients admitted to the intensive 
care unit (ICU) found that MBL variant genotypes and low MBL levels were associated 
with increased risk of sepsis [37]. However, a European study of 1839 patients admitted 
to critical care units with sepsis caused by community-acquired pneumonia or peritoni-
tis and 477 controls found no increased risk of sepsis-related mortality at 28 days or six 
months [38]. In most studies of patients receiving chemotherapy, MBL deficiency was 
associated with more prolonged episodes of febrile neutropenia and serious infections, 
such as bacteremia [8,39,40]. However, this association was not seen in patients who 
were severely neutropenic or who had acute myeloid leukemia, most likely because 
the significant impairment in phagocytosis in these patients blunted any effect of MBL 
deficiency [8,41,42].
In people with no other identified immunodeficiency
MBL deficiency may be clinically relevant in some individuals who do not have other 
predisposing factors. Low MBL levels are associated with increased susceptibility to 
meningococcal disease, tuberculosis, and Legionnaires’ disease; recurrent tonsillitis, 
malaria, and vulvovaginitis; and poor immune response to influenza vaccination [43-54], 
although higher levels are associated with an increased risk of leprosy [55,56]. Low levels 
of MBL are also associated with more severe disease and worse outcomes with certain 
infections, including community-acquired pneumonia [57], invasive pneumococcal dis-
ease [58-61], Escherichia coli-induced pyelonephritis [62], Chlamydia trachomatis genital 
tract infections [63], and hepatitis B virus infection [43,55,64,65]. Results regarding the 
role of MBL in hepatitis C infection are inconsistent [66-69].
A higher prevalence of severe MBL deficiency (MBL level ≤50 ng/mL) was seen in one 
case-control study of patients with a history of recurrent and/or severe infections, par-
ticularly respiratory tract infections [70]. This difference persisted even in the absence 
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of concomitant immunodeficiency. However, the existence of other cofactors that influ-
ence the clinical phenotype in patients with MBL deficiency was suspected in this study 
for several reasons. Patients with severe MBL deficiency and recurrent  and/or  severe 
infections had a broad spectrum of clinical severity. No correlation was seen between 
severe MBL deficiency and severity of infection. Onset of recurrent  and/or  severe in-
fections was not until adolescence or adulthood despite presumed longstanding MBL 
deficiency. In addition, a number of control subjects with no significant infection history 
had severe MBL deficiency.
The role of MBL in human immunodeficiency virus (HIV) infection and progression has 
been debated for several years. MBL is able to bind to the envelope protein of the HIV-1 
virus (gp120) because it is highly glycosylated with N-linked carbohydrates [71,72]. Thus, 
it is conceivable that MBL-mediated complement activation could facilitate the immune 
response directed against HIV infection. However, reports on the effects of MBL on HIV 
infection and progression are contradictory. Results on the effect of MBL on HIV disease 
progression have ranged from finding no effect [73-75] to a negative effect of high MBL 
and a beneficial effect of low MBL [76,77]. However, subsequent literature seems to point 
towards a beneficial effect of high MBL levels and a negative effect of low MBL [78-91].
Autoimmunity
In the presence of MBL deficiency, chronic inflammatory conditions may be more severe. 
Low MBL serum levels and MBL2 genetic polymorphisms with corresponding impaired 
MBL function appear to affect several autoimmune diseases, although the data are 
sometimes inconsistent.
It is generally assumed that the recognition of self-determinants is confined to the 
adaptive immune system and that the innate immune system plays little role in autoim-
munity. However, evidence is growing that the innate immune system may contribute 
to autoimmunity, either by priming or promoting aggressive immune responses [92,93].
A major pathophysiologic concept of autoimmunity is impaired apoptotic cell clear-
ance. MBL facilitates the clearance of apoptotic cells [94,95]. Membrane carbohydrates 
are altered when a cell goes into apoptosis, leading to increased expression of fucose and 
N-acetyl-glucosamine [96,97]. Redistribution or clustering of glycoproteins expressed 
on apoptotic cells may enable MBL to bind to these carbohydrates, thereby facilitating 
clearance [98,99].
Rheumatoid arthritis
The data on the effect of MBL levels and rheumatoid arthritis are variable, depending 
upon patient factors and outcomes studied [100-106]. Early disease onset and findings 
linked with poor prognosis, including reactive systemic amyloidosis and increased joint 
erosions and inflammation, are generally associated with low MBL levels [100-105]. 
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(See “Investigational biologic markers in the diagnosis and assessment of rheumatoid 
arthritis” and “HLA and other susceptibility genes in rheumatoid arthritis”.)
However, a dose-dependent association was seen between MBL2 expression potential 
(indicated by structural genotypes and promoter polymorphisms) and disease activity 
and physical disability in anticyclic citrullinated peptide-positive patients with newly 
diagnosed rheumatoid arthritis [107]. This finding is in accord with previous findings of 
increased serum concentrations of MBL in patients with rheumatoid arthritis [108].
MBL deficiency does not increase susceptibility to juvenile idiopathic arthritis (JIA), 
but it is associated with a younger age at onset of polyarticular JIA [109]. On the other 
hand, MBL-deficient children with oligoarticular JIA are more likely to go into remission 
than MBL-sufficient children.
Systemic lupus erythematosus
There are mixed reports regarding the relationship between MBL deficiency and systemic 
lupus erythematosus (SLE), although, on balance, low MBL levels are associated with SLE 
[110-112]. (See “Epidemiology and pathogenesis of systemic lupus erythematosus”.)
Autoantibodies against MBL are more commonly elevated [113] and MBL levels 
lower [114] in patients with quiescent rather than active SLE. Anti-MBL autoantibodies 
in SLE patients can influence functional activity of MBL and have a significant role in 
SLE disease pathogenesis [115]. MBL-downregulating promoter polymorphisms were 
associated with juvenile-onset SLE and higher risk of cutaneous manifestations and car-
diopulmonary complications [67]. Low serum MBL levels also predisposed patients with 
SLE to more major infections, particularly bacterial infections [68,114]. In addition, SLE 
patients with MBL-deficient genotypes were more likely to have cardiovascular disease 
[69] and increased intima-media thickness of the common carotid artery [116], although 
these findings may be due to the association of this genotype with antiphospholipid 
antibodies. High MBL expression genotypes were associated with an increased risk of 
renal disorders in children with SLE [114].
In contrast, one study found that there was no increase of severe MBL deficiency in 
SLE, nor an association between low MBL levels and infection [71]. Another study found 
that MBL genotype status did not affect the course or outcome of the disease [72].
Celiac disease
The MBL O/O genotype is associated with celiac disease and an increased risk of devel-
oping secondary autoimmune diseases [117].
Diabetes
Data regarding the association between MBL levels and early onset of diabetes mellitus 
(DM) are conflicting. One study found higher levels of MBL in children with type 1 DM 
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than in siblings without diabetes or in healthy controls [118]. Conversely, another study 
found that individuals who developed type 1 DM during childhood and adolescence 
were more likely to possess a variant allele than healthy controls [119]. The association 
between MBL levels and diabetic microvascular complications is discussed below. 
(See ‘Cardiovascular disease’ below.)
Ischemia/reperfusion injury
Tissue damage and impaired organ function as a result of ischemia/reperfusion (I/R) in-
jury remain major hurdles in solid organ transplantation. MBL may contribute to the 
pathogenesis of inflammation-induced vascular damage both in the transplanted organ 
and in the recipient’s native blood vessels [120]. The hypoxic state to which an organ is 
subjected during organ harvesting, transport, and implantation results in activation of 
various immunologic events [121]. The complement system plays an important role in 
mediating tissue injury after oxidative stress. Activation and deposition of complement 
on the vascular endothelium occurs following oxidative stress [122,123]. Tissue injury 
after I/R is significantly reduced by complement inhibition [92,124]. Complement activa-
tion via the lectin pathway occurs following oxidative stress, indicating that inhibition of 
MBL could be a novel approach in reducing I/R damage [125].
MBL depositions are observed early after transplantation of ischemically injured 
kidneys [126]. In addition, high MBL levels are associated with a more severe form of 
rejection leading to graft loss in kidney, heart, and lung transplantation [127-129]. Graft 
and patient survival following simultaneous pancreas and kidney transplantation (SPKT) 
is significantly better in recipients with MBL gene polymorphisms associated with low 
MBL levels. These findings identify higher levels of MBL as a potential risk factor for graft 
and patient survival in solid organ transplantation.
Infection risk in solid organ transplantation patients is discussed above. (See ‘In im-
munocompromised hosts’ above.)
Cardiovascular disease
MBL binds to intracellular components of endothelial cells during I/R injury, activating 
the lectin pathway [93,125]. The association between MBL levels and cardiovascular 
disease is variable, with some outcomes more commonly associated with high levels 
and others with low levels.
In a prospective study performed in patients with severe carotid atherosclerosis, 
the degree of early restenosis was significantly higher in patients homozygous for the 
normal MBL2 genotype (allele A) compared with patients with MBL2 variant genotypes 
[130].
After cardiac surgery, patients with MBL deficiency did not develop multiple organ 
dysfunction syndrome, unless they had been transfused with fresh frozen plasma 
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(containing MBL from donors), suggesting that sustained MBL deficiency is a favorable 
status for patients undergoing cardiac surgery [131]. However, in another study, patients 
expressing the combined MBL2 LYQA high-secretor haplotype had a significantly higher 
incidence of postoperative myocardial infarction after primary coronary artery bypass 
graft surgery than patients who do not express this haplotype [132].
High MBL levels were also associated with an increased risk of ischemic heart disease 
and myocardial infarction [133] and risk of both cardiovascular death and death from all 
causes [134] in a cohort of Danish patients with rheumatoid arthritis. However, a large 
Norwegian health study showed that variant MBL2 haplotypes causing MBL deficiency 
were associated with a twofold higher risk of myocardial infarction in a young to middle-
aged Caucasian population [135].
A major source of mortality and morbidity in DM is microvascular complications. A 
substantial portion of patients with diabetes develops diabetic nephropathy and reti-
nopathy. Higher levels of MBL are associated with diabetic microvascular complications. 
Several studies show an association between an increased risk of developing renal fail-
ure and high MBL-producing genotypes in patients with diabetes [136-138], although 
this relationship is inconsistent [139]. The exact immunologic processes involving the 
role of MBL in the pathogenesis of diabetic nephropathy are still unclear. In contrast, 
high MBL levels may predict a decreased likelihood of myocardial infarction in patients 
with diabetes [140].
Cerebrovascular disease
MBL and the lectin pathway of complement activation may play a role in the patho-
genesis of stroke. MBL in cerebrospinal fluid (CSF) is predominantly brain derived, 
most likely from the leptomeningeal cells. There is a negligible physiologic connection 
between the MBL fractions in CSF and serum [141]. In a murine model, MBL null mice 
were protected from transient and permanent ischemic injury [142]. In addition, poly-
man2, a synthesized mannosylated molecule that binds to MBL, improved neurologic 
deficits and infarct volume when given up to 24 hours after brain ischemia was induced 
in wild-type mice. A study in human stroke patients found that serum MBL levels were 
significantly higher acutely in ischemic stroke patients compared with normal controls, 
and serum levels of MBL correlated with the stroke score [143].
Cancer
The MBL genotype appears to influence oncologic disease. Low MBL-producing variants 
are associated with increased risk of gastric cancer and more advanced phenotypes 
[144-146]. In addition, MBL-deficient oncologic patients that require surgery have 
a higher risk of developing postoperative complications. However, the opposite is 
seen with promoter polymorphisms. The X allele of the Y/X  promoter polymorphism 
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(resulting in lower MBL levels) is associated with improved lung cancer survival [147]. 
Promoter polymorphisms that result in higher MBL levels are associated with increased 
susceptibility to human papillomavirus infection [148] but not increased risk for cervical 
cancer [149]. MBL deficiency, defined as an MBL level <200 ng/mL, was associated with 
decreased event-free survival in pediatric oncology patients [150]. MBL substitution 
therapy improved the outcome in patients with advanced pancreatic cancer [151].
Trauma
Complement activity is virtually abolished immediately following severe trauma. Plasma 
MBL levels are inversely correlated with injury severity [152]. Serum levels of MBL nadir 
at 12 hours posttrauma, with levels subsequently rising to more than threefold the 
levels seen in controls at 10 days posttrauma [153]. Severely injured patients with single 
nucleotide polymorphisms (SNPs) in MBL2 are significantly more susceptible to having 
positive cultures, infectious complications, systemic inflammatory response syndrome 
(SIRS), and septic shock than patients with an MBL2 wild-type genotype [154].
DIAGNOSIS
Mannose-binding lectin (MBL) deficiency is generally defined as a serum level <500 ng/
mL  or MBL activity below 200  units/mL,  depending upon the assay used. However, 
physiologically relevant MBL levels may vary depending upon the associated disease 
state, with reported cutoffs ranging from 100 to 1000 ng/mL [39,40,155,156]. In addition, 
serum concentrations of lectin pathway components, including MBL, vary depending 
upon age of the patient [157]. Thus, some groups have defined MBL deficiency as partial 
(>50 to 1000 ng/mL) or severe (≤50 ng/mL) in adults [70,158,159], and others suggest 
a cutoff of <100 ng/mL for MBL deficiency in children [29]. Antigenic measurement of 
MBL serum concentration is becoming a widely available diagnostic test. However, there 
is no consensus on the relevance of MBL deficiency or its treatment. Thus, there are no 
standard guidelines regarding which patients to test.
Indications for testing
The authors suggest performing an evaluation of all arms of the complement system 
(classical, alternative, and lectin pathways) in individuals with recurrent and/or severe 
respiratory tract infections and in patients immunocompromised for other reasons, such 
as transplantation patients with recurrent infections who have decreased cellular immu-
nity due to immunosuppressive drug therapy, since these are the patients most likely to 
benefit from the antibiotic prophylaxis and treatment. Testing includes total hemolytic 
complement (CH50), alternative pathway hemolytic (AH50), and MBL assays. This testing 
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is reviewed in greater detail separately. (See “Overview and clinical assessment of the 
complement system”.)
There is no role for routine testing of MBL genotype or serum concentration in children 
with chronic wet cough [160].
Laboratory evaluation
Impairment of the lectin pathway is almost always due to MBL defects. In addition, 
there is a strong correlation between MBL serum concentration and MBL activity. Thus, 
antigenic measurement of MBL serum concentration is an appropriate screening test 
for MBL deficiency. However, this method will not detect rarer causes of impairment of 
the lectin pathway due to mutations in the mannan-binding lectin-associated protease 
(MASP) or ficolin genes. The activation assay is an alternative test that can detect impair-
ment due to MBL, MASP, or ficolin defects [161]. Separate testing for opsonic activity is 
not necessary, since it is always low in cases of MBL deficiency. (See “Inherited disorders 
of the complement system”, section on ‘Lectin pathway deficiencies’.)
Further evaluation by functional tests or genotyping is usually not necessary. Testing 
only by genotyping is not recommended, because MBL levels can differ by 10-fold in 
individuals with identical genotypes for all of the known MBL variants [159]. In addi-
tion, patients with low levels of MBL can be missed by genotyping for only the exon 1 
variants but not the promoter polymorphisms (eg, patients with the LXPA haplotype 
would be grouped with those with normal MBL levels). The other components of the 
lectin pathway, the MASPs and ficolins, can be analyzed if the  MBL2  gene is normal. 
(See ‘Genetics’ above.)
TREATMENT
General management
Patients with recurrent infections should be treated similarly to other patients with 
complement deficiencies. This includes prompt treatment with antibiotics with each 
febrile infection and possible prophylactic antibiotics, as is done with patients who are 
postsplenectomy or who have symptomatic immunoglobulin A (IgA) deficiency. In ad-
dition, these patients should receive pneumococcal and meningococcal vaccines, with 
documentation of antibody responses. A trial of intravenous  immune globulin  (IVIG) 
may be indicated if infections are recurrent and severe and a plasma opsonic defect 
is identified. (See “Selective IgA deficiency: Clinical manifestations, pathophysiology, 
and diagnosis”  and  “Secondary immunodeficiency due to underlying disease states, 
environmental exposures, and miscellaneous causes”  and “Inherited disorders of the 
complement system”.)
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MBL substitution therapy
Animal studies and  phase-I/II  human studies suggest that replacement therapy with 
plasma-derived MBL is safe. However, it is still an experimental treatment and not avail-
able commercially [155,162-165]. Recombinant human MBL protein (rhMBL), derived 
from a Chinese hamster ovary cell line, is untested and is also not commercially available 
[166].
One plasma-derived MBL substitution product previously available was administered 
intravenously and had a relatively short half-life [167]. The mean half-life of plasma-
derived MBL is approximately 70 hours (range 15 to 115) in healthy adult volunteers 
and adult patients with Staphylococcus aureus septicemia and approximately 36 hours 
(range 24 to 67) in children with chemotherapy-induced neutropenia. In a study of 10 
pediatric oncology patients with chemotherapy-induced neutropenia who received 
twice-weekly MBL infusions, all patients reached trough MBL levels of ≥1  mcg/mL,  a 
level sufficient for opsonization in healthy individuals [168]. However, these patients all 
had suboptimal levels of opsonophagocytosis. Insufficient opsonic function may be due 
to additional complement deficiencies in these patients.
SUMMARY
•	 Mannose-binding lectin (MBL) is a protein involved in complement activation via 
the lectin pathway (figure 1). As part of the innate immune system, the complement 
system provides immediate defense against infection and has proinflammatory ef-
fects. (See ‘Introduction’ above.)
•	 Decreased levels of MBL can result from mutations in the MBL2 gene or its promoter. 
People with mutations of both MBL2 alleles constitute approximately 3 to 5 percent 
of the population. Heterozygosity is found in up to 30 percent of the population. 
(See “Mannose-binding lectin”, section on ‘The MBL gene’ and ‘Epidemiology’ above.)
•	 MBL binds to carbohydrates on microbes or unwanted material and triggers the 
activation of the lectin pathway, but it does not recognize self-carbohydrates. 
(See “Mannose-binding lectin”, section on ‘The MBL protein’ and “Mannose-binding 
lectin”, section on ‘The lectin pathway’ and “Complement pathways”.)
•	 Plasma levels of MBL are stable over time. Serum levels of MBL range from less 
than 20 up to 10,000 ng/mL. Deficiency of MBL is typically defined as a serum level 
<500 ng/mL. (See “Mannose-binding lectin”, section on ‘The MBL protein’ and ‘Physi-
ology’ above and ‘Diagnosis’ above.)
•	 Individuals generally benefit from normal levels of MBL. However, in some cases, low 
levels appear to be advantageous. (See ‘Clinical manifestations’ above.)
82 Chapter 5
•	 In certain individuals, deficiency of MBL is associated with an increased frequency 
of pyogenic infections, especially encapsulated bacteria, due to defective opsoniza-
tion. (See ‘Infection’ above.)
•	 In the presence of MBL deficiency, chronic inflammatory conditions may be more 
severe. MBL can also alter the response that affected individuals have to a variety of 
medical conditions. (See’Autoimmunity’ above.)
•	 The management of symptomatic patients include appropriate immunizations, 
measuring antibody responses to these vaccines, prompt use of antibiotics with 
infections, and possible use of prophylactic antibiotics. Intravenous immune globu-
lin (IVIG) is an option if infections are refractory and severe and a plasma opsonic de-
fect is present. MBL substitution therapy is generally unavailable and as yet untested. 
(See ‘MBL substitution therapy’ above.)
Use of UpToDate is subject to the Subscription and License Agreement.
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ABSTRACT
Background. Infectious complications remain a serious threat to polytraumatized 
patients. Susceptibility and response to infection is, in part, heritable. The lectin path-
way plays a major role in innate immunity. The aim of this study was to assess if single 
nucleotide polymorphisms (SNPs) in three key genes within the lectin pathway affect 
susceptibility to infectious complications in severely injured patients.
Methods. A prospective cohort of trauma patients admitted to a Level I Trauma Cen-
ter between January 2008 and April 2011 was genotyped for SNPs in MBL2 (Mannose-
Binding Lectin 2), MASP2 (MBL-Associated Serine Protease 2), and FCN2 (Ficolin 2). 
Association of genotype with prevalence of infection was tested with chi-square and 
logistic regression analysis.
Results. A total of 219 patients were included, of which 112 (51%) developed a posi-
tive culture in either sputum, wounds, blood, or urine. Systemic Inflammatory Response 
Syndrome (SIRS) developed in 140 patients ( 64%), sepsis in 79 (36%), and septic shock in 
37 (17%). Patients with a MBL2 exon 1 variant allele were more prone to positive wound 
cultures (OR 2.50, p=0.025). A MASP2 Y371D DD genotype predisposed for SIRS (OR 4.78; 
p=0.042) and septic shock (OR 2.53; p=0.003). A FCN2 A258S AS genotype predisposed 
for positive wound cultures (OR 3.37; p=0.005) and septic shock (OR 2.18 p=0.011).
Conclusion. Severely injured patients with SNPs in MBL2, MASP2 Y371D and FCN2 
A258S of the lectin pathway of complement activation are significantly more susceptible 
to positive culture findings and to infectious complications, SIRS and septic shock than 
patients with a common (wildtype) genotype. 
Sequence variation in the lectin pathway 97
INTRODUCTION
Trauma is the leading cause of death for young people. Early mortality due to exsan-
guination seems to have decreased (1), probably as a result of improvements in pre-
hospital and early in-hospital care. Sepsis (3.1-17.0%) and multiple organ dysfunction 
syndrome (1.6-9.0%) remain unchanged as important causes of late trauma-related 
mortality (1). Severe sepsis and septic shock are responsible for 30-50% of all deaths in 
Intensive Care Units (2). Moreover, sepsis, multiple organ dysfunction syndrome, and 
infectious complications such as pneumonia and wound infection increase hospital 
costs (3). Prevention of infections and identifying patients at risk deserves full attention.
The lectin pathway of complement activation plays a critical role in innate immunity 
(Figure 1). Severe injury poses a serious challenge to the immune system (4). Dysregu-
lation of the systemic inflammatory response to  injury is central to the development 
of acute respiratory distress syndrome, multiple organ failure and sepsis (5). Levels of 
complement factor C3a are already markedly increased at the scene of trauma. More-
over, complement function decreases dramatically within four hours after trauma, and 
does not return to normal in as much as five days. Complement activation correlates 
with injury severity, reduced tissue hypoperfusion as measured with base deficit, and 
adverse clinical outcomes (6). The pathological basis for these conditions is attributed to 
immune dysfunction (7). An understanding of the mechanisms of innate immune activa-
tion and alarmins following trauma may lead to new therapeutic agents and improved 
patient survival (7).
The ability of the complement system to be activated depends on the genetic integrity 
of the coding genes (6). Genetic variation, particularly Single Nucleotide Polymorphisms 
(SNPs), in innate immunity genes may play a central role in development of posttrau-
matic complications (8). Key genes in the lectin pathway are MBL2 (Mannose-Binding 
Lectin 2), MASP2 (MBL-Associated Serine Protease 2), and FCN2 (Ficolin 2). SNPs in all 
three genes and their promoter regions, have been associated with infectious diseases.
SNPs in exon 1 (codons 52, 54, and 55) of the MBL2 gene, which encodes Mannose-
Binding Lectin, cause transition from an A to a D, B, or C allele (which are all three known 
as 0 alleles).  An A0 or 00 genotype as well as the presence of an YX promoter SNP results 
in a dramatic reduction in MBL concentration compared with the common AA genotype 
(9). MBL deficiency has been associated with an increased risk of infectious disease in, 
among others, pediatric and ICU patients (10).
MBL-associated serine-proteases (MASPs) are activated upon binding of MBL or ficolin 
to pathogen-associated molecular patterns located on the surface of bacteria or viruses. 
MASPs circulate in plasma in complexes with MBL and with ficolins 2 and 3 (11). Of the 
known MASPs MASP2 is the main initiator of the lectin complement pathway (12,13). 
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The MASP2 D120G and Y371D SNPs have been associated with pneumococcal disease 
and to increase the risk of infectious complications after liver transplantation (14,15,16).
The FCN2 gene encodes for L-ficolin (Ficolin-2), a pattern recognition molecule. The 
FCN2 T236M and A258S SNPs have been shown to influence infectious outcome after 
liver transplantation (16), peritoneal dialysis (17), perinatal infection in babies and respi-
ratory infections (18), but largely the functional impact of these SNPs is unknown (19).
There are many reports on MBL levels, genetic variations in immune genes and sus-
ceptibility to infections in different kinds of populations such as surgical patients, burn 
patients, or ICU/sepsis patients (20-22), but the relevance of SNPs in the lectin comple-
ment pathway coding genes (MBL2, MASP2 and FCN2) in severely injured  patients 
is unknown. The aim of this study was therefore to determine the influence of lectin 
complement pathway SNPs on the susceptibility and course of infectious complications 
in severely injured patients. 
PATIENTS AND METhODS
Patients and Clinical Data
A prospective cohort of consecutive severely injured patients admitted to a Level I 
Trauma Center between January 2008 and April 2011 was studied. Eligibility criteria 
were an Injury Severity Score (ISS) (23) of 16 or higher and age 18-80 years. Patients 
with a known immune disorder or those taking immunosuppressive medication were 
excluded. Patients with a neutrophil count of <1x109 cells/L before the onset of sepsis, 
infections associated with burns, or lack of commitment to full life-support measures 
by the primary physician were also excluded. After obtaining written informed consent 
from patient or proxy a blood sample was taken in an EDTA tube and stored at -80°C. The 
study was approved by the local medical research ethics committee and was registered 
in the Dutch Trial Registry under NTR1625.
Cultures were taken on a standardized routine basis or at the discretion of the physi-
cian based upon clinical signs. Endpoints used were: positive cultures during hospital 
stay, SIRS within the first 24 hours of admission and developing sepsis (primary end-
point), septic shock and mortality during hospital admission. SIRS, sepsis, and septic 
shock were defined using international criteria (24). The following data were retrieved 
from electronic files: age at trauma, trauma mechanism, ISS score, length of stay in the 
ICU and the hospital, all positive cultures from blood, urine, sputum, wounds, or other 
positive cultures during hospital stay, if patients developed SIRS within 24 hours of 
hospital admission and sepsis or septic shock during the hospital stay, and if applicable 
the cause of death.
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DNA Isolation
Genomic DNA was isolated from 300 µL EDTA-treated peripheral blood using the 
QIAamp® DNA Blood Mini kit (QiaGen Benelux, Venlo, The Netherlands), according to 
the manufacturer’s instructions. The purity (A260nm/A280nm index) and concentration 
of the isolated DNA samples were determined with the Thermo Scientific Nanodrop 
TM1000 spectrophotometer (Isogen Life Science, De Meern, The Netherlands). Samples 
were diluted to 10 ng/µL using Milli-Q and were stored at 4°C until use.
PCR Oligonucleotides
Details on the SNPs studied are given in Supplementary Table 1. SNP data were retrieved 
from Ensembl.org, National Center for Biotechnology Information (NCBI) GenBank, and 
NCBI SNP Database. All oligonucleotides (see Supplementary Table 2) were purchased 
from Eurogentec (Seraing, Belgium). Primers for MBL2 amplify a 103-bp fragment over-
lapping the SNPs in exon 1. For the High Resolution Melting Analysis (HRMA) of all other 
SNPs 18-20 nucleotides upstream and downstream of the SNPs were used as forward and 
reverse primers. Oligonucleotides for direct sequencing were designed using the Oligo 
6.22 software (Molecular Biology Insight, Cascade, CO), and resulted in 400-555 base pair 
amplicons. Oligonucleotides had melting temperatures (Tm) between 65.0-66.5°C (Tm 
calculated using the nearest neighbor method at a salt concentration of 50mM KCl and 
4mM MgCl2 (303mM of Na+ equivalent) and 300nM oligonucleotides).
Genotyping
SNPs were detected using HRMA (25). Polymerase chain reactions (PCRs) were per-
formed in a total volume of 10µL, containing 20ng genomic DNA, 5pmol of both gene-
specific oligonucleotides, 2pmol dNTPs (Promega, Madison, WI), 1µL LC-green (Bioké, 
Leiden, The Netherlands), 0.5U of Taq DNA polymerase (Roche Diagnostics, Almere, The 
Netherlands), and 1µl 10x PCR buffer containing 20mM MgCl2. Two pmoles of calibrator 
oligonucleotides were added for calibration of melting curves. Reaction mixtures for the 
detection of MBL2 exon 1 SNPs contained 1pmol forward and 5pmol reverse oligonucle-
otide and 5pmol probe. The PCR was run on a Biometra Thermocycler (Biometra GmbH, 
Göttingen, Germany). The thermocycling program included denaturation at 95°C for 10 
min, followed by 55 cycles of 20 sec at 95°C, 30 sec at 60°C and 40 sec at 72°C, and a final 
extension step of 5 min at 72°C. HRMA was performed using a LightScanner® (HR-96, 
Idaho Technology, Salt Lake City, USA). Melting was done from 55°C to 98°C at 0.1°C/sec. 
Melting curves were analyzed with the LightScanner® Software using Call-IT 1.5. Typical 
examples are shown in Figure 2.
All variant genotypes were confirmed by direct sequencing. PCR were performed in 
a total volume of 25µL, containing 50ng genomic DNA, 4mM MgCl2, 3pmol of both oli-
gonucleotides, 2pmol dNTPs, 1.0U Taq DNA polymerase, and 1µl 10x PCR buffer without 
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MgCl2. The thermocycling program included denaturation at 95°C for 5 min, followed by 
35 cycles of 30 sec at 95°C, 1 min at 60°C, and 1 min at 72°C, and a final step of 7 min at 
72°C. Amplicon purification and sequencing was performed by BaseClear (Leiden, The 
Netherlands). Results were analyzed using the SeqMan® analysis software.
Statistical Analysis
Allele frequencies for each SNP were determined by gene counting. The genotype distri-
bution of each SNP was tested for departure from the Hardy-Weinberg equilibrium. The 
Hardy-Weinberg equilibrium is a principle stating that the genetic variation in a popula-
tion will remain constant from one generation to the next in the absence of disturbing 
factors. In the χ2  analysis the observed genotype frequencies are tested against the 
expected genotype based on the Hardy-Weinberg principle. A p-value <0.05 indicates 
deviation from theHardy-Weinberg equilibrium.
Data were analyzed using the Statistical Package for the Social Sciences, version 16.0 
(SPSS, Chicago, Ill., USA). Binary logistic regression models were developed in order to 
model the relation between different covariates and the occurrence of an infectious 
complication. Herein, age, gender, injury severity score, and trauma mechanism (i.e., 
blunt or penetrating injury) were added as covariates. A p-value of <0.050 was consid-
ered to be statistically significant. 
RESULTS
Patient Demographics
During the study period, 219 patients were included. Of all patients 177 (77.6%) were 
male, the median age was 44 years (P25-P75 27-56) and the median ISS score was 25 (P25-
P75 18-29). A total of 13 patients (5.9%) sustained penetrating trauma and 159 (72.6%) 
were admitted to the ICU with a median stay of 3 (P25-P75 0-14) days. Trauma mechanisms 
are shown in table 1.
Table 1. Demographics of trauma mechanisms
Traffic accidents 48%
Falls from height 32%
Crush injury to thorax 6%
Street fighting 3%
Gunshot wounds 2%
Stabbing 2%
Horseriding accidents 2%
Miscellaneous accidents 5%
Miscellaneous injuries include collapsing buildings, helicopter crash, ice skating, kitesurfing, fireworks.
Sequence variation in the lectin pathway 101
Figure 1. Schematic illustration of the Lectin pathway of complement activation
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Genetic variation in MBL2, MASP2, and FCN2 results in protein deficiency or diminished 
protein activity. This in turn reduces the ability to encounter pathogen attacks and increases 
the susceptibility to the onset and course of infections. 
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High-Resolution LightScanner CCD camera image of fluorescent LC-Green dye in 
a 96 well plate at the start of High Resolution Melting Analysis. 
High-Resolution LightScanner CCD camera image of fluorescent LG-Green dye in a 96-wells plate at the 
start of High Resolution Melting Analysis
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Example of Normalized Melting Peaks following High Resolution Melting Analysis (HRMA) 
showing different genotypes found in a 96 wells plate following PCR of MBL2 exon1. 
 
 
 
Example of sequencing of codons 52, 54 and 57 of MBL2 exon 1 showing different 
mutations. 
 
Example of Normalized Melting Peaks following High Resolution Melting Analysis (HRMA) showing differ-
ent genotypes found in a 96 wells plate following PCR of MBL2 exon1.
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Example of Normalized Melting Peaks following High Resolution Melting Analysis (HRMA) 
showing different genotypes found in a 96 wells plate following PCR of MASP2 D120G.                        
 
 
Example of MASP2 exon 3 heterozygous D120G mutation detected by sequencing. 
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Example of MASP2 exon 3 heterozygous D120G mutation detected by sequencing. 
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Genotype Frequencies
HRMA showed that 131 (59.8%) of all patients were wildtype for the MBL2 exon 1 poly-
morphism, 72 (32.9%) patients carried the heterozygote A0 genotype, and 16 (7.3%) 
patients the homozygote 00 genotype. Of the A0 patients, 34 (15.5%) had an AB geno-
type, 13 (5.9%) AC, and 25 (11.4%) AD. The 00 group consisted of five BB, three BC, three 
BD, four CD, and one DD genotype. Seventy-four patients (33.8%) were heterozygous 
for the MBL2 YX SNP, all other patients had the common YY genotype. For the MASP2 
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Example of Normalized Melting Peaks following High Resolution Melting Analysis (HRMA) 
showing different genotypes found in a 96 wells plate following PCR of MASP2 Y371D. 
 
 
 Example of MASP2 exon 9 heterozygous Y371D mutation detected by sequencing. 
Example of Normalized Melting Peaks following High Resolution Melting Analysis (HRMA) showing differ-
ent genotypes found in a 96 wells plate following PCR of MASP2 Y371D.
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D120G SNP 207 (94.5%) patients had the common DD genotype; the remaining 5.5% 
percent were DG. For the MASP2 Y371D SNP 145 (66.2%) were YY, 60 (27.4%) YD, and 14 
(6.4%) DD. For the FCN2 T236M SNP 106 (48.4%) had a TT, 97 (44.3%) a TM and 16 (7.3%) 
a MM genotype. For the FCN2 A258S SNP 168 (76.7%) had an AA, 47 (21.5%) and AS, 
and 4 (1.8%) a SS genotype. Linkage disequilibrium was noted for the MBL2 YX (χ2=9.05; 
P=0.003) and MASP Y371D (χ2=4.72; P=0.030); the genotype distribution of the other 
SNPs was in agreement with the Hardy-Weinberg equilibrium (χ2=0.11-1.86; P=0.173-
0.736).
Effect of Genotype on Infectious Complications
Table 2 shows an overview of infectious complications encountered separated by 
genotype. Overall, Gram-positive bacteria were detected in 79 patients (36%), Gram-
negative bacteria in 84 (38%) and fungi in 46 (21%). Approximately half of the patients, 
112 (51.1%), developed a positive culture; this was mostly in sputum in70 patients, but 
positive cultures were also found in wounds in 36 patients, blood (N=32), and urine 
(N=32). A total of 139 patients (63%) developed SIRS within 24 hours, of which 79 (57%) 
developed sepsis and 37 (27%) septic shock. Thirteen (5.9%) patients died.
Table 3 shows the results of the multivariable logistic regression models. Patients with the 
MBL2 exon 1 heterozygous A0 variant were at significantly increased risk for developing 
positive wound cultures (Odds Ratio, OR, 2.51; 95% CI 1.12-5.62; p=0.025). Twenty-five 
percent of A0 patients developed a positive wound culture versus 11.5% of patients with 
the common AA genotype (Table 2). The risk of Gram-positive or Gram-negative organ-
isms was unaltered by the MBL2 exon 1 genotype. Patients with an A0 or 00 genotype 
had a consistently higher rate of SIRS, sepsis, and septic shock than patients with an AA 
genotype (Table 2); however, no statistically significant associations between MBL2 exon 
1 genotype and these endpoints were found in the multivariable analysis.
The presence of a MBL2 YX promoter SNP was a significant risk factor for a fungal 
culture (OR 2.32; 95% CI 1.08-4.96; p=0.030; Table 3); in 27.0% of YX patients a fungus 
was cultured (mainly Candida albicans from pulmonary aspirates) versus 17.9% of YY 
patients. No other significant associations were found for the YX genotype.
For the MASP2 D120G genotype polymorphism we found no statistically significant 
differences for all endpoints although, strikingly, fungi, positive blood cultures and septic 
shock were only found in DD patients (22.2%, 15.5%, and 17.9%, respectively). Another 
striking, yet non-significant, finding was that only 8.3% of DG patients developed sepsis 
versus 37.7% in DD patients (p=0.060).
Carrying a MASP2 Y371D DD variant genotype was a risk factor for developing SIRS 
within 24 hours after hospital admission (OR 4.78; 95% CI 1.06-21.59; p=0.042); SIRS 
developed in 78.6% of homozygous DD patients versus 58.6% of patients with a com-
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mon YY genotype. Patients with the MASP2 Y371D DD variant were also at significantly 
increased risk for developing septic shock (OR 2.53; 95%CI 1.12-4.33; p=0.003; Table 3); 
35.7% of patients with a DD genotype developed a septic shock versus 23.3% in the DG 
and 12.4% in the YY group (Table 2). The prevalence of Gram-positive culture findings in 
patients with a MASP2 Y371D DD genotype was 50% (versus 33% in the YY group), how-
ever this was not statistically significantly different (OR 3.19; 95% CI 0.95-10.71; p=0.060).
No significant associations between the FCN2 T236M genotype and infectious events 
were found. A noteworthy finding was that positive blood cultures developed in 16.5% 
of patients with a TM variant genotype and in 25.0% of patients with a variant MM 
genotype, versus only 11.3% of patients with the common TT genotype; both were not 
statistically significant in the multivariate model (p=0.560 and p=0.092, respectively).
Heterozygosity for the FCN2 A258S SNP was associated with increased risk of positive 
wound cultures (OR 3.37; 95%CI 1.45-7.85; p=0.005); positive culture findings were seen 
in 29.8% of AS patients versus 12.5% in AA patients. In addition, a FCN2 A258S AS geno-
type significantly increased the risk of developing septic shock (27.7% in heterozygous 
AS patients versus 14.3% of AA patients; OR 2.18; 95%CI 1.30-4.78; p=0.011). Strikingly, 
the prevalence of Gram-negative bacteria in FCN2 A258S AS patients was 48.9% (versus 
34.5% in the AA group), yet this did not reach statistical significance (OR 1.87; 95% CI 
0.93-3.77; p=0.079).
DISCUSSION
In this study the association between single nucleotide polymorphisms (SNPs) in 
three important genes (MBL2, MASP2 and FCN2) of the innate immune system and the 
susceptibility of severely injured patients to positive culture findings and infectious 
complications has been investigated. The MBL2 exon 1 A0 genotype was associated 
with increased rates of positive wound cultures, whereas the YX genotype of the MBL2 
promotor region increased the rates of colonization with fungi. The MASP2 Y371D DD 
genotype put the patient at increased risk for SIRS and septic shock, and the FCN2 A258S 
AS genotype was a risk factor for positive wound cultures and septic shock.
Trauma is the leading cause of death among young adults and infection is one of the 
major causes of late deaths among trauma patients. Prevention of infection in trauma 
patients is therefore of great clinical importance. Finding the association between dif-
ferent SNPs and infection risk is a first step in creating a genetic risk profile for infection 
susceptibility. In the future this may lead to the development of preventive measures 
for patients who are found to be at risk. The development of infectious complications is 
multifactorial in origin but genetic variation in the innate immune system may be one 
such important factor
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The genotype distributions of MBL2 (21,26,27),  MASP2 D120G (14),  MASP2 Y371D (16), 
FCN2 T236M (16), and FCN2 A258S (16,28) were in agreement with published data on 
European patients. All five genotypes were in agreement with the Hardy-Weinberg equi-
librium, indicating that the allele and genotype frequencies of all SNPs in the population 
remain in equilibrium from generation to generation.
The MBL2 exon 1 A0 genotype was significantly associated with an increased risk of 
developing a positive wound culture. This has been demonstrated before in a murine 
model of burn wounds (29) but is a novel finding in human trauma patients. Also, 
heterozygosity in the MBL2 YX promoter region conferred a risk for developing fungal 
colonization (mainly C. albicans) with YX patients having a 10% higher frequency of 
fungi than patients with the common YY genotype. The MBL2 exon 1 genotype seemed 
unrelated to Gram-positive or Gram-negative organisms as causative micro-organisms, 
while others found MBL2 0/0 to be associated with a higher incidence of Gram-positive 
bacteria (26). Although the percentage of patients with a MBL2 A0 or 00 genotype that 
developed SIRS, sepsis, or septic shock was higher than in wildtype AA patients, this 
difference was not statistically significant. In a Danish ICU cohort study, the MBL 00 and 
to a lesser extent MBL A0 genotypes were significantly associated with mortality after 
sepsis (26). 
In the current study only twelve patients carried a MASP2 D120G DG genotype, which 
prevalence is similar as published before (14). In DG patients, a consistent trend was not-
ed towards lower rates of infection, sepsis and septic shock as compared to DD patients, 
yet statistical power was too low to reach statistical significance. Lack of association 
with bacteraemia was also described for patients admitted to an ICU in Belgium (21). In 
that study, however, mortality was increased in patients with a MASP2 D120G DG or GG 
genotype. The MASP2 D120G polymorphism has also been associated with pneumococ-
cal disease and to increase the risk of infectious complications after liver transplantation 
(14-16). As no relevant information is available, the importance of genetic variation in 
MASP2 for injured patients yet has to be elucidated in a larger cohort.
In this study, the rare MASP2 Y371D DD genotype increased the risk for developing 
SIRS and septic shock. in a univariate model in patients undergoing liver transplanta-
tion this association was not found (15). No further data on trauma and intensive care 
patients are available for this polymorphism. 
For the FCN2 T236M SNP we found no statistically significant association with any 
of the endpoints. In  previous studies FCN2 T236M was found to predispose to bacte-
rial infection after liver transplantation (15), and to infection in patients on continuous 
ambulatory peritoneal dialysis (17), but no data on trauma or patients in the ICU are 
available.
The FCN2 A258S AS genotype was significantly associated with positive wound cul-
tures (13% to 25%) and with septic shock (6% to 25%) in our cohort. This SNP produces 
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the lowest serum levels of ficolin-2 (30). This SNP  was found to be related to earlier onset 
of P. aeruginosa colonization in patients with cystic fibrosis (31) and to cytomegalovirus 
infection after liver transplantation (16), but largely the functional impact of this SNP is 
unknown (19).
The strength of this study is that we assessed the relevant SNPs in the lectin pathway 
as a whole. Some genotypes were found very infrequently. Although this study is among 
the largest studies assessing the contribution of genotype differences to infection sus-
ceptibility in trauma patients, the sample size is not large enough yet to answer all ques-
tions. For instance, it was not large enough to assess the roles of the genotypes studied 
Table 2. Demographic description of positive cultures and infectious complications by genotype
Geno
type
N (%) Sputum
Culture
Blood
Culture
Urine
Culture
Wound
Culture
SIRS * Sepsis * Septic
Shock *
Entire 
population
219 70 (32.0) 32 (14.6) 32 (14.6) 36 (16.4) 139 (63.5) 79 (36.4) 37 (16.9)
MBL2 Exon 1** AA 131 44 (33.6) 17 (13.0) 21 (16.0) 15 (11.5) 81 (61.8) 44 (33.6) 19 (14.5)
A0 72 21 (29.2) 15 (20.8) 11 (15.3) 18 (25.0) 49 (68.1) 31 (43.1) 15 (20.8)
00 16 5 (31.2) 0 (0.0) 0 (0.0) 3 (18.8) 9 (56.2) 4 (25.0) 3 (18.8)
MBL2 YX YY 145 47 (32.4) 21 (14.5) 22 (15.2) 26 (17.9) 88 (60.7) 54 (37.2) 27 (18.6)
YX 74 23 (31.1) 11 (14.9) 10 (13.5) 10 (13.5) 51 (68.9) 25 (33.8) 10 (13.5)
XX 0 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
MASP2 D120G DD 207 68 (32.9) 32 (15.5) 30 (14.5) 35 (16.9) 132 (63.8) 78 (37.7) 37 (17.9)
DG 12 2 (16.7) 0 (0.0) 2 (16.7) 1 (8.3) 7 (58.3) 1 (8.3) 0 (0.0)
GG 0 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
MASP2 Y371D YY 145 45 (31.0) 17 (11.7) 22 (15.2) 19 (13.1) 85 (58.6) 48 (33.1) 18 (12.4)
YD 60 20 (33.3) 14 (23.3) 7 (11.7) 13 (21.7) 43 (71.7) 24 (40.0) 14 (23.3)
DD 14 5 (35.7) 1 (7.1) 3 (21.4) 4 (28.6) 11 (78.6) 7 (50.0) 5 (35.7)
FCN T236M TT 106 32 (30.2) 12 (11.3) 18 (17.0) 19 (17.9) 69 (65.1) 36 (34.0) 15 (14.2)
TM 97 31 (32.0) 16 (16.5) 13 (13.4) 16 (16.5) 61 (62.9) 36 (37.1) 18 (18.6)
MM 16 7 (43.8) 4 (25.0) 1 (6.3) 1 (6.3) 9 (56.2) 7 (73.8) 4 (25.0)
FCN2 A258S AA 168 53 (31.5) 23 (13.7) 22 (13.1) 21 (12.5) 107 (63.7) 58 (34.5) 27 (14.3)
AS 47 17 (36.2) 9 (19.1) 9 (19.1) 14 (29.8) 30 (63.8) 19 (40.4) 13 (27.7)
SS 4 0 (0.0) 0 (0.0) 1 (25.0) 1 (25.0) 2 (50.0) 2 (50.0) 0 (0.0)
* SIRS, sepsis and septic shock were only determined for patients admitted to the Intensive Care Unit.
** The wildtype is referred to as A, while the variant genotype is referred to as 0
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for rare outcomes such as mortality. It also limits the evaluation of combinations of SNPs. 
Increasing the sample size will allow us to overcome these limitations. A final limitation 
of this study relates to the multitude of statistical tests applied in order to assess the 
relevance of several SNPs to multiple outcome measures. The authors acknowledge that 
not applying a multiple comparison correction may result in falsely accepting a spurious 
relation. However, a Bonferroni correction would be a too stringent correction and may 
result in falsely denying true effects. Presenting the 95% confidence intervals for all odds 
ratio’s allows readers, who will mainly be interested in a specific gene or effect, to value 
the results.
In summary, the results of the current study clearly show that SNPs in MBL2, MASP2 
and FCN2 influence the susceptibility to positive cultures and severity of infection in 
severely injured trauma patients. The development of infectious complications is mul-
tifactorial in origin but genetic variation in the innate immune system may be one such 
important factor. Finding the association between different SNPs and infection risk is a 
first step in creating a genetic risk profile for infection susceptibility. In the future this 
may lead to the development of preventive measures for patients who are found to 
be at risk. Substitution therapy would be one way to overcome deficiencies caused by 
genetic variation. MBL substitution therapy phase I trials have already shown interesting 
results (32-36).
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Supplementary Table 1. Positions of SNPs and their corresponding nucleotide and amino acid transition
Gene SNP dbSNP ID Nucleotide 
transition
(Accession code)
Amino-Acid 
transition
(Accession code)
Location on gene / 
Domain
MBL2 D allele rs5030737 5219C>T Arg52Cys Exon 1, collagenous region
B allele rs1800450 5226G>A Gly54Asp Exon 1, collagenous region
C allele rs1800451 5235G>A Gly57Glu Exon 1, collagenous region
Y-221X rs7096206 4776C>G
(NG_008196.1)
N.A.
(NP_000233.1)
Promoter, 5’untranslated 
region
MASP2 D120G rs72550870 5620A>G
(NG_007289.1) 
Asp120Gly
(NP_006601.2)
Exon 3, CUB1 
Y371D rs12711521 21370T>G
(NG_007289.1)
Tyr371Asp
(NP_006601.2)
Exon 9, CCP 
FCN2 T236M rs17549193 11369C>T Thr236Met Exon 8, fibrinogen-like 
domain
A258S rs7851696 11434G>T
(NG_011649.1)
Ala258Ser
(NP_004099.2)
Exon 8, fibrinogen-like 
domain
SNP, Single Nucleotide Polymorphism;
Amino acids: Ala (A), Alanine; Arg (R), Arginine; Asp (D), Asparctic acid; Cys (C), Cysteine; Gly (G), Glycine; Glu 
(E), Glutamic acid; Met (M), Methionine; Ser (S), Serine; Thr (T), Threonine; Tyr (Y), Tyrosine
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Supplementary Table 2. Oligonucleotide sequence for primers and probes used in MBL2, MASP2 and FCN2 
genotyping
Name
(Accession 
code)
SNP Assay Primer
/probe
Start 
Position
Sequence
Calibrators - HRMA Forward - 5’- TTAAATTATAAAATATTTAT AATATTAATTATATA
TATATAAATATAATA-Amine-C6-3’
Reverse - 5’- TATTATATTTATATATATAT
AATTAATATTATAAA
TATTTTATAATTTAA-Amine-C6-3’
MBL2 B, C, D HRMA Forward 5163 5’-CTGCAGTGATTGCCTGTAGC-3’
(NG_008196.1) Reverse 5246 5’-GCCCAACACGTACCTGGTTC-3’
Probe 5207 5’-GGCAAAGATGGGCGTGATGGC
ACCAAGGGA-Amine-C6-3’
Seq Forward 5033 5’-TTCCCTGAGTTTTCTCACA-3’
Reverse 5430 5’-GGCTGGCAAGACAACTATT-3’
YX HRMA Forward 4755 5’-CCCATTTGTTCTCACTGCCA-3’
Reverse 4777 5’-AAGACTATAAACATGCTTTC-3’
Seq Forward 4392 5’-CAGGGCCAACGTAGTAAG-3’
Reverse 4886 5’-TTGTGACACTGCGTGACT-3’
MASP2 D120G HRMA Forward 5600 5’-GGACATTACCTTCCGCTCCG-3’
(NG_007289.1) Reverse 5621 5’-ACGGCTTCTCGTTGGAGTAG-3’
Seq Forward 5313 5’-ACCTCTGCGAGTACGACT-3’
Reverse 5733 5’-TGCCTGGCCTAAGACA-3’
Y371D HRMA Forward 21350 5’-TTGACTGTGGCCCTCCTGAT-3’
Reverse 21371 5’-CACTCGGCCACTGGGTAGAT-3’
Seq Forward 21171 5’-CTCGGCTTTTTAACCTTTC-3’
Reverse 21695 5’-ACCATTTGGAATACATTGTGT-3’
FCN2 T236M HRMA Forward 11349 5’-CTGCACAGGAGATTCCCTGA-3’
(NG_011649.1) Reverse 11370 5’-AGGACTGGTTGTTGTGGAAC-3’
A258S HRMA Forward 11414 5’-ATCTTAACACCGGAAATTGT-3’
Reverse 11435 5’-AGCTCCCTGAAACATCACAG-3’
T236M, 
A258S
Seq Forward 11186 5’-CAGCAGGGCAGTATTCAC-3’
Reverse 11541 5’-TATCCTTTCCCCGACTTC-3’
 HRMA, High-Resolution Melting Analysis.
Seq: Sequencing
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INTRODUCTION
Trauma is a leading cause of morbidity and mortality, and many polytraumatized patients 
require treatment in an Intensive Care Unit (1). Infectious complications are common af-
ter trauma and may substantially affect morbidity and mortality. Sepsis and subsequent 
multiple organ failure are the predominant causes of late mortality in polytraumatized 
patients; sepsis may occur in 3.1-17.0% and multiple-organ failure may occur in 1.6-9.0% 
of trauma patients (2). Immunogenetic biomarkers have been proposed as contributing 
factors in the development of trauma-induced infection and organ failure (3-5).
Toll-like receptor (TLR) signalling plays an important role in the innate immune re-
sponse and has been associated with the activation of inflammatory immune responses 
during trauma-induced infections (6, 7). TLRs recognize and bind to a wide range of 
pathogen-associated molecular patterns (PAMPs) on bacteria, viruses, fungi, and 
protozoa. This binding leads to the transcriptional activation of genes encoding for 
pro-inflammatory cytokines, chemokines, and co-stimulatory molecules, which subse-
quently control the activation of antigen-specific adaptive immune response (5, 8, 9).
To date, ten different TLRs are described in humans (TLR1-10), each binding to differ-
ent PAMPs and initiating specific immunological responses (10, 11). TLR2 heterodimers 
bind polypeptides in the cell walls of bacteria and signal via MyD88 following initial 
interaction with Cluster of Differentiation 14 (CD14) (12, 13). TLR4 forms a homodimer 
complex with the MD-2 protein after initial binding of lipopolysaccharide (LPS) expressed 
by Gram-negative bacteria to CD14 (14). TLR9 is present in various cells of the immune 
system, such as dendritic cells and B- and T-cells and is situated intracellularly, bound to 
the endosome. TLR9 binds to the unmethylated cytosine guanine dinucleotide (CpG) 
motifs, present in bacterial and viral DNA but also in our mitochondrial DNA. Thus this 
receptor recognizes pathogens as well as damaged tissue (9, 15).
CD14 is a central pattern recognition molecule in innate immunity (16). It is found 
in association with TLRs on the surface of monocytes, macrophages, neutrophils, and 
hepatocytes (17, 18), and as a soluble form in serum (19). CD14 acts as coreceptor of 
TLR2 and TLR4 for the detection of various microbial PAMPs (20), and initiates immune 
responses through TLR2 and TLR4 signalling (17, 21).
There is growing evidence that susceptibility and response to infectious disease is, in 
part, heritable; particularly Single Nucleotide Polymorphisms (SNPs) in innate immune 
response genes may play a key role (22-25). Two important SNPS in the TLR2 gene (i.e., 
T-16934A and R753Q) have been associated with Gram-positive infections, sepsis and 
septic shock (12, 13, 26). SNPs in the TLR4 gene (i.e., D299G and T399I) may alter the 
responsiveness of TLR4 to LPS, and increase the risk of Gram-negative sepsis, bactere-
mia, and mortality in patients admitted to the Intensive Care Unit (ICU) (4, 27, 28). SNPs 
in the TLR9 gene promoter (i.e., T-1237C and T-1486C), affect transcription regulation 
122 Chapter 7
resulting in a disabled TLR9 function. A variant T-1273C genotype has been associated 
with increased susceptibility to viral pneumonia (29). The CD14 C-159T SNP has been 
associated with sepsis and Gram-negative bacteremia (26, 30, 31).
The aim of this study was to assess the relevance of SNPs in TLR2, TLR4, TLR9, and 
CD14 for infectious complications in trauma patients. We hypothesized that these SNPs 
are associated with increased prevalence of positive cultures (Gram-positive and Gram-
negative bacteria and fungi), systemic inflammatory response syndrome (SIRS), sepsis, 
and septic shock in trauma patients.
MATERIALS AND METhODS
Patients and Data Collection
A prospective cohort of consecutive polytraumatized patients admitted to a Level I 
Trauma Center (Rotterdam, The Netherlands) between January 2008 and April 2011 was 
studied. Eligibility criteria were an Injury Severity Score (ISS) (32) of 16 or higher and 
age 18-80 years. Patients with a known immune disorder or those taking immunosup-
pressive medication were excluded. Patients with a neutrophil count of <1x109 cells/L 
before the onset of sepsis, infections associated with burns, or lack of commitment to 
full life-support measures by the primary physician were also excluded. The ISS score 
was calculated using the ISS update 98. After obtaining written informed consent from 
patient or proxy a blood sample was taken in an EDTA tube and stored at -80°C until use. 
The study was approved by the local medical research ethics committee and the trial 
was registered in the Dutch Trial Registry (NTR1625) before patient recruitment.
Cultures were taken on a standardized routine basis or at the discretion of the physi-
cian based upon clinical signs. Endpoints used were: positive cultures during hospital 
stay, mortality, SIRS within the first 24 hours of admission and developing sepsis or 
septic shock during hospital admission. SIRS, sepsis, and septic shock were defined us-
ing international criteria (33). The following data were retrieved from electronic files: 
age at trauma, trauma mechanism, ISS score, length of stay in the Intensive Care Unit 
and the hospital, all positive cultures from blood, urine, sputum, wounds, or other posi-
tive cultures during hospital stay, if patients developed SIRS within 24 hours of hospital 
admission and sepsis or septic shock during the hospital stay, and if applicable the cause 
of death.
DNA Isolation
Genomic DNA was isolated from 300 µL EDTA-treated peripheral blood using the 
QIAamp® DNA Blood Mini kit (QiaGen Benelux, Venlo, The Netherlands), according to 
the manufacturer’s instructions. The purity (A260nm/A280nm index) and concentration 
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of the isolated DNA samples were determined with the Thermo Scientific Nanodrop 
TM1000 spectrophotometer (Isogen Life Science, De Meern, The Netherlands). Samples 
were diluted to 10 ng/µL using Milli-Q and were stored at 4°C until use.
PCR Oligonucleotides
Details on the SNPs studied are given in Table 1. SNP data were retrieved from Ensembl.
org, National Center for Biotechnology Information (NCBI) GenBank, and NCBI SNP 
Database. All oligonucleotides (see Table 2) were purchased from Eurogentec (Seraing, 
Belgium). For the High Resolution Melting Analysis (HRMA) 18-20 nucleotides upstream 
and downstream of the SNPs were used as forward and reverse primers. Oligonucle-
otides for direct sequencing were designed using the Oligo 6.22 software (Molecular 
Biology Insight, Cascade, CO, USA) and resulted in 400-555 base pair amplicons. Oligo-
nucleotides had melting temperatures (Tm) between 65.0-66.5°C (Tm calculated using 
the nearest neighbour method at a salt concentration of 50mM KCl and 4mM MgCl2 
(303mM of Na+ equivalent) and 300nM oligonucleotides).
Table 1. Positions of SNPs and their corresponding nucleotide and amino acid transition
Gene SNP dbSNP ID Nucleotide 
transition
(Accesion code)
Amino-Acid 
transition
(Accesion code)
Location on gene / Domain
TLR2 T-16934A rs4696480 6686T>A N.A. Promoter, 5’ untranslated 
region
R753Q rs5743708 25877G>A
(NG_016229.1)
Arg753Gln
(NP_003255.2)
Exon 3; Toll/Interleukin-1 
receptor (TIR) domain
TLR4 D299G rs4986790 13843A>G Asp299Gly Exon 3 Extracellular domain
T399I rs4986791 14143C>T
(NG_011475.1)
Thr399Ile
(NP_612564.1)
Exon 3 Extracellular domain
TLR9 T-1486C rs187084 52261031A>G N.A. Promoter, 5’ untranslated 
region
T-1237C rs5743836 52260782A>G
(NC_000003.11)
N.A. Promoter, 5’ untranslated 
region
CD14 C-260T rs2569190 5371T>C
(NG_023178.1)
N.A. Promoter, 5’ untranslated 
region
SNP, Single Nucleotide Polymorphism;
Amino acids: Arg (R), Arginine; Asp (D), Asparctic acid; Gln (Q), Glutamine; Gly (G), Glycine; Ile (I), Isoleucine; 
Thr (T), Threonine.
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Genotyping
SNPs were detected using HRMA (34). Polymerase chain reactions (PCRs) were performed 
in a total volume of 10 µL, containing 20ng genomic DNA, 5pmol of both gene-specific 
oligonucleotides, 2pmol dNTPs (Promega, Madison, WI, USA), 1µL LC-green (Bioké, 
Leiden, The Netherlands), 0.5U of Taq DNA polymerase (Roche Diagnostics, Almere, The 
Netherlands), and 1µl 10x PCR buffer containing 20mM MgCl2. Two pmoles of calibrator 
oligonucleotides were added for calibration of melting curves. The PCR was run on a 
Biometra Thermocycler (Biometra GmbH, Göttingen, Germany). The thermocycling 
program included denaturation at 95°C for 10 min, followed by 55 cycles of 20 sec at 
95°C, 30 sec at 60°C and 40 sec at 72°C, and a final extension step of 5 min at 72°C. HRMA 
was performed using a LightScanner® (HR-96, Idaho Technology, Salt Lake City, UT, USA). 
Melting was done from 55°C to 98°C at 0.1°C/sec. Melting curves were analyzed with the 
LightScanner® Software using Call-IT 1.5.
All variant genotypes found were confirmed by direct sequencing. PCR were per-
formed in a total volume of 25 µL, containing 50 ng genomic DNA, 4mM MgCl2, 3pmol of 
both oligonucleotides, 2pmol dNTPs, 1.0U Taq DNA polymerase, and 1µl 10x PCR buffer 
without MgCl2. The thermocycling program included denaturation at 95°C for 5 min, 
followed by 35 cycles of 30 sec at 95°C, 1 min at 60°C, and 1 min at 72°C, and a final step 
of 7 min at 72°C. Amplicon purification and sequencing was performed by BaseClear 
(Leiden, The Netherlands). Results were analyzed using the SeqMan® analysis software.
Data Analysis
Allele frequencies for each SNP were determined by gene counting. The genotype 
distribution of each SNP was tested for departure from the Hardy-Weinberg equilibrium 
by means of χ2 analysis. Data were analyzed using the Statistical Package for the Social 
Sciences, version 16.0 (SPSS, Chicago, IL, USA). Categorical variables were analyzed us-
ing a χ2 test or a Fischer’s exact test in order to determine whether the SNPs predisposed 
for a higher risk of any of the endpoints. A Mann-Whitney U-test was used for statistical 
analysis of numeric variables. Binary logistic regression models were developed in order 
to model the relation between different covariates and the occurrence of an infectious 
complication. Herein, age, gender, injury severity score, and trauma mechanism (i.e., 
blunt or penetrating injury) were added as covariates. A p-value of <0.05 was considered 
to be significant. 
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RESULTS
Patient demographics and genotype frequencies
From January 2008 to April 2011, 219 patients were included. Of all patients 177 (77.6%) 
were male, the median age was 44 years (P25-P75 27-56) and the median ISS score was 
25 (P25-P75 18-29). A total of 13 patients (5.9%) sustained penetrating trauma and 159 
patients (72.6%) were admitted to the ICU with a median stay of 3 days (P25-P75 0-14). 
Trauma mechanisms included traffic accidents (48.9%), fall from height (32.4%), crush 
injury to the chest (4.1%), head injuries with axes or screwdrivers (2.7%), gunshot inju-
ries (2.3%), horseback injuries, street fighting, stab wounds (1.8%), and miscellaneous 
injuries like ice skating, helicopter crash, fireworks or collapsing buildings.
HRMA results showed that TLR2 T-16934A rare alleles were abundantly present; 58 
(26.5%) patients had a homozygous AA genotype, 111 (50.7%) had a heterozygous TA 
genotype, and 50 (22.8%) carried a wild-type TT genotype. For the TLR2 R753Q SNP, 15 
(6.8%) patients carried the heterozygote RQ and 204 (93.2%) a RR genotype. For the TLR4 
D299G SNP 190 (86.8%) had a DD, and 28 (12.8%) a DG genotype. The TLR4 T399I SNP 
cosegregated with D299G in 217 (99.1%) patients; 191 (87.2%) had a TT, 26 (11.9%) a TI, 
and 2 (0.9%) an II genotype. For the TLR9 T-1486C SNP, 80 (36.5%) had a TT, 100 (45.7%) 
a TC, and 39 (17.8%) a CC genotype. For the TLR9 T-1237C SNP, 160 (73.1%) had a TT, 52 
(23.7%) a TC, and 7 (3.2%) a CC genotype. For the CD14 C-159T SNP, 59 (26.9%) had a CC, 
105 (47.9%) a CT, and 55 (25.2%) a TT genotype. The genotype distribution of all SNPs 
was in agreement with the Hardy-Weinberg equilibrium (χ2=0.01-1.149; P=0.275-0.997).
Effect of genotype on infectious complications
Table 3 shows an overview of infectious complications encountered separated by 
genotype. Overall, Gram-positive bacteria were detected in 79 patients, Gram-negative 
bacteria in 84 and fungi in 46 patients. Approximately half of the patients (51.1%) 
developed a positive culture; this was mostly in sputum (N=70), but positive cultures 
were also found in wounds (N=36), blood (N=32), and urine (N=32). Overall, 139 patients 
developed SIRS within 24 hours, of which 79 developed sepsis and 37 septic shock. 
Thirteen (5.9%) patients died.
Table 4 shows the results of the multivariable logistic regression models. Sustaining a 
Gram-positive infection was statistically significantly increased in patients with a TLR2 
T-16934A TA genotype (Odds Ratio, OR, 2.816; 95%CI 1.249-6.348; p=0.013). Forty-one 
percent of TA patients cultured a Gram-positive bacterium versus 24.0% of wildtype 
patients (Table 3). A TLR9 T-1486C rare allele, on the other hand, seemed to result in 
decreased Gram-positive rates (31.0% in TC and 30.8% in CC versus 45.0% in wildtypes), 
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however this did not reach statistical significance in the multivariable analyses (p=0.066 
for TC and p=0.079 for CC).
None of the SNPs affected the risk of Gram-negative cultures or fungi. Although the 
rate of positive fungal cultures seemed reduced in patients with a TLR9 T-1486C TC geno-
type (14.0% versus 27.5% in wildtypes) and increased in patients with a CD14 C-159T CT 
 17
 
Example of Normalized Melting Peaks obtained with LightScanner following High 
Resolution Melting Analysis (HRMA) showing different genotypes found in a 96 wells plate 
following PCR of TLR4 T399I. 
 
 
 
Example of sequencing of TLR4 exon 3 which shows a heterozygous TI genotype at T399I. 
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genotype (23.8% versus 13.6% in wildtypes), both were not statistically associated with 
outcome in multivariable analyses (p=0.060 and 0.072, respectively).
As for the location of the positive cultures, the TLR2 T-16934A AA genotype was sig-
nificantly associated with fewer positive urine cultures (OR 0.230; 95%CI 0.060-0.886; 
p=0.033). Blood cultures occurred in 17.1% of TLR2 T-16934A TA patients (versus 8.0% 
in TT) and in 23.1% of TLR9 T-1237C TC patients (versus 12.5% in TT), but both were not 
statistically significant in multivariable analysis (p=0.065 and p=0.076, respectively). The 
occurrence of sputum and wound cultures was unrelated to any of the SNPs studied.
The occurrence of SIRS in the first 24 hours of hospital admission was statistically 
significantly increased in patients with a TLR2 T-16934A TA genotype (OR 2.386; 95%CI 
1.011-5.632; p=0.047), but unrelated to any of the other SNPs. Sepsis and septic shock 
were unrelated to TLR2, TLR4, TLR9, and CD14 SNPs.
DISCUSSION
In this study we showed that severely injured trauma patients with an inadequately 
functioning TLR pathway due to SNPs in TLR2 and, to a lesser extent, in TLR9 are at 
increased risk of infectious complications.
The genotype distributions of all polymorphisms studied in our trauma patient cohort 
were in agreement with published data (4, 13, 26, 28-30, 35-41). The genotype distribu-
tions of all SNPs were in agreement with the Hardy-Weinberg equilibrium model.
Patients with a TLR2 T-16934A TA genotype were more prone to Gram-positive infec-
tions, and presence of homozygous AA alleles predisposed patients to SIRS. Sutherland 
et al. showed that this SNP is a risk factor for sepsis and Gram-positive bacteremia in 
critically ill patients in the ICU (26). We were unable to confirm their findings related to 
sepsis; 38.7% of our trauma patients with a TA genotype developed sepsis versus 36.0% 
of patients with a TT genotype. We found a 2-fold higher rate of positive blood culture in 
the TA group compared with the TT group (p=0.065). More patients are needed to reach 
statistical significance. Our finding that the T-16934A AA genotype was associated with 
fewer positive urine cultures (N=4) has not been shown before. Only Gram-negative 
bacteria were found.
The TLR2 R753Q SNP has been associated with increased prevalence of Gram-positive 
infections, staphylococcal infections, sepsis, and septic shock (12, 13, 28, 42), but others 
reported that this SNP did not affect the risk of bacteremia in Caucasian patients admit-
ted to the ICU (4). With only 6.8% having an RQ genotype and complete absence of a QQ 
genotype, our study was inadequately powered to find any associations with outcome 
in trauma patients. If this SNP were relevant, it would only be so in a small subset of 
patients.
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TLR4 is important in the defense against bacteria, particularly Gram-negative bacteria. 
Since both the D299G and T399I SNP are associated with decreased TLR4 function it 
is remarkable that we did not find any association of these SNPs with infection sus-
ceptibility. However, both SNPs were previously shown to be unrelated to outcome of 
Gram-negative sepsis (43) and to sepsis in trauma patients with SIRS in the ICU (13). 
Several other studies, however, did in fact imply that TLR4 polymorphisms were related 
to increased susceptibility to infections and sepsis in burn patients (44) or in patients 
admitted to an ICU (4, 28, 42, 45).
Shalhub et al. showed that a TLR4 D299G variant G allele caused a decreased rate of 
complicated sepsis in Caucasian trauma patients admitted to the ICU (45). Our multi-
variable analysis did not support an association between genotype and infection or 
outcome of sepsis; almost 50% of patients with sepsis developed septic shock, both in 
the DG and TI group (5 of 11 patients) and in wildtypes (32 of 68 patients). 
Our data support the findings of Henckaerts et al. Who showed that a TLR4 D299G 
variant genotype resulted in a 2-fold increase of bacteremia in ICU patients (4).
Reduced expression of TLR9 could render patients more susceptible to pathogens, yet 
increased TLR9 expression after stimulation by damage-associated molecular patterns 
(DAMPs) could trigger an exaggerated immune response (15, 46, 47). The TLR9 T-1486C 
SNP has been associated with sepsis and multiple organ dysfunction (MOD) in trauma 
patients (37), puerperal group A streptococcal sepsis (48), and invasive fungal infections 
in paediatric patients receiving chemotherapy (49). We found a trend towards reduced 
prevalence of Gram-positive bacteria and fungi for this SNP (p=0.060-0.066), but no 
significant association with SIRS, sepsis, or septic shock. As opposed to our results, how-
ever, Chen et al. showed that patients with a T-1486C variant genotype were at increased 
risk of sepsis (OR 1.36) and had slightly increased MOD scores (37).
We found a trend towards increased risk of positive blood cultures the T-1237C TC 
genotype (p=0.076), but no significant association with SIRS, sepsis, or septic shock. In 
agreement with our data, Chen et al. found no association between TLR9 T-1237C variant 
genotype and infection in severe blunt trauma patients (37). 
The CD14 C-159T SNP reduces the promoter activity of CD14, resulting in decreased 
TLR2/4 downstream signalling. A CT or TT genotype has been associated with increased 
rates of positive bacterial culture findings and Gram-negative sepsis in critically ill 
patients (26, 30, 31, 41). However, in other studies this SNP was not associated with 
altered risk of Gram-negative infection or sepsis in critically ill patients (28, 51), and was 
unrelated to sepsis prevalence and severity in trauma patients (45, 52). Our data support 
the latter.
A limitation of our study is that we retrospectively collected data on clinical manifesta-
tions of infection like SIRS, sepsis, and septic shock. Also, cultures were initially collected 
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at the discretion of the physician based on clinical parameters but during the study 
protocols changed towards routine culturing of all patients.
The human innate immune system consists of more pathways in addition to the TLR/
CD14 pathway. The advantage of our study is that the growing DNA bank of severely 
injured trauma patients enables us to increase the panel of SNP assays or even perform 
a genome-wide SNP analysis.
In summary, our data showed that an aberrant functioning of the TLR/CD14 pathway 
due to presence of the TLR2 T-16934A polymorphism predisposed severely injured 
trauma patients to increased risk of developing an infectious complication. The TLR9 
T-1486C SNPs on the other hand may reduce the risk of positive culture findings, and 
TLR4 variation was unrelated to infection. Additional research is needed in order to fully 
understand the roles these SNPs play in the complex injury and infection processes.
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ABSTRACT
Introduction Trauma is the leading cause of death for people under 45 years of age. 
Infection and Multiple Organ Dysfunction Syndrome remain important causes of 
morbidity for those who survive the initial trauma. Identification of trauma patients at 
risk for developing infectious complications may improve outcome and cut costs. This 
study aimed to investigate the effects of genetic sequence variations in innate immune 
response genes on outcome in severely injured patients.
Methods From January 2008 to June 2015 severely injured trauma patients were in-
cluded at a Level 1 University Trauma Center. DNA was extracted and Single Nucleotide 
Polymorphisms (SNP) in eight innate immune response genes (MBL2, MASP2, FCN2, 
TLR2, TLR4, TLR9, CD14 and NOD2) were amplified by Polymerase Chain Reaction (PCR) 
and analyzed by High Resolution Melting Analysis (HRMA). Patients were prospectively 
monitored for positive culture findings, Systemic Inflammatory Response Syndrome 
(SIRS), sepsis, septic shock, and mortality. 
Results A total of 410 severely injured trauma patients were included with a median 
ISS of 25. The risk of urine infection was influenced by SNPs in CD14, wound cultures by 
SNPs in MBL2 and FCN2, SIRS by SNPs in MASP2, and septic shock and mortality by SNPs 
in MASP2 and TLR9. A genetic risk model confirmed that a combination of specific SNPs 
could possibly be used as a prediction model for infectious complications in the future.
Conclusions Single Nucleotide Polymorphisms in specific innate immune response 
genes increase the risk of infectious outcome in severely injured trauma patients.
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INTRODUCTION
Infectious complications threaten the recovery of severely injured trauma patients. The 
initial trauma, surgery (the ‘second hit’), and admittance to a surgical ICU ward puts 
patients at increased risk of developing infectious complications resulting in compli-
cated recovery, prolonged hospital stay, increased mortality risk, and increased costs to 
society (1, 2). 
A number of risk factors have already been defined that put trauma patients at 
increased risk for developing complications. These include injury severity score (ISS) 
and Revised Trauma Score (RTS) (1, 3), Glasgow Coma Score (1, 2), age (2), gender (4), 
mechanical ventilation (5), multiple surgical procedures (5), multiple blood transfusions 
(5), comorbidity (1), and spinal cord injury (5).
The immune response between groups of trauma patients with and without late 
infectious complications differs already shortly after trauma (6). Sequence variations in 
specific innate immune response genes are considered to be variables in the develop-
ment of these different immune responses which may increase the risk for infectious 
complications, Systemic Inflammatory Response Syndrome (SIRS), sepsis, septic shock, 
and Multiple Organ Dysfunction Syndrome (MODS) (7-13). 
The aim of this study was to determine the influence of sequence variations in innate im-
mune response genes on the risk of developing infectious complications in a prospective 
cohort of severely injured patients. Sequence variations were used to calculate genetic 
risk scores. Finally, a prediction model was developed in order to study if these genetic 
risk scores contributed to the identification of high-risk groups. Early identification of 
high-risk groups may decrease complications and lower hospital resource utilization.
MATERIALS AND METhODS
Patients and Data Collection
Materials and methods shall be discussed briefly since they were published before (12, 
13). A prospective cohort of consecutive polytraumatised patients admitted to a Level 
I Trauma Center (Rotterdam, The Netherlands) between January 2008 and June 2015 
was studied. Eligibility criteria were an Injury Severity Score (ISS) (3) of 16 or higher and 
aged 18 to 80 years old. After obtaining written informed consent from patient or proxy, 
a blood sample was taken in an EDTA tube and stored at -80 °C until use. The study was 
approved by the local Medical Research Ethics Committee and the study was registered 
in the Dutch Trial Registry (NTR1625) before patient recruitment.
Cultures were taken on a standardised routine basis or at the discretion of the physi-
cian based upon clinical signs. Endpoints used were: positive cultures during hospital 
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stay, SIRS within the first 24 hours of admission, development of sepsis or septic shock, 
or mortality during hospital admission. SIRS, sepsis, and septic shock were defined using 
international criteria (14). 
DNA Isolation
Genomic DNA was isolated from 300 µL EDTA-treated peripheral blood using the 
QIAamp® DNA Blood Mini kit (QiaGen Benelux, Venlo, The Netherlands), according to 
the manufacturer’s instructions. The purity (A260nm/A280nm index) and concentration 
of the isolated DNA samples were determined with the Thermo Scientific Nanodrop 
TM1000 spectrophotometer (Isogen Life Science, De Meern, The Netherlands). Samples 
were diluted to 10 ng/µL using Milli-Q and were stored at 4 °C until use.
PCR Oligonucleotides
Details on the SNPs studied are given in Table 1. SNP data were retrieved from Ensembl.org, 
National Center for Biotechnology Information (NCBI) GenBank, and NCBI SNP Database. 
Genotyping
SNPs were detected using High Resolution Melting Analysis (HRMA) as described before 
(15). Polymerase chain reactions (PCRs) were performed as described before (12, 13). 
HRMA was performed using a LightScanner® (HR-96, Idaho Technology, Salt Lake City, 
UT, USA). Melting was done from 55 °C to 98 °C at 0.1 °C/sec. Melting curves were anal-
ysed with the LightScanner® Software using Call-IT 1.5.
All variant genotypes found were confirmed by direct sequencing. PCRs were 
performed as described before (12, 13). Amplicon purification and sequencing was 
performed by BaseClear (Leiden, The Netherlands). Results were analysed using the 
SeqMan® analysis software.
Data Analysis
Allele frequencies for each SNP were determined by gene counting. The genotype 
distribution of each SNP was tested for departure from the Hardy-Weinberg equilibrium 
by means of χ2 analysis. Data were analysed using the Statistical Package for the Social 
Sciences, version 16.0 (SPSS, Chicago, IL, USA).
HaploReg v4.1 (http://www.broadinstitute.org/mammals/haploreg/haploreg.php; ac-
cessed February 08, 2016) was used for exploring linkage disequilibrium (LD) between SNPs 
within the same gene in four continental populations (i.e. African, American, Asian, and Eu-
ropean). A correlation coefficient (r2) or D’ value of 0.8 or larger was considered indicative of 
significant LD. In that case only one of the SNPs was used in the genetic risk score calculation.
Categorical variables were analysed using a χ2 test or a Fischer’s exact test in order 
to determine whether the SNPs predisposed for a higher risk of any of the endpoints. 
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A Mann-Whitney U-test was used for statistical analysis of numeric variables. Binary 
logistic regression models were developed in order to model the relation between dif-
ferent covariates and the occurrence of an infectious complication. In the initial model, 
age, gender, injury severity score, and individual SNPs were added as covariates. Next, 
similar models were developed in which an overall or data-driven genetic risk score was 
calculated and added as covariate instead of the individual SNPs. A p-value of <0.05 
was considered to be statistically significant. The added effect of the genetic risk score 
on discriminating between patients with versus without infectious complications was 
further visualised by generating Receiver Operator Curves (ROC) curves and by comput-
ing the Area Under the ROC (AUC).
Table 1. Positions of SNPs and their corresponding nucleotide and amino acid transition
Gene SNP dbSNP ID Nucleotide transition
(Accession code)
Amino-Acid transition
(Accesion code)
MBL2 D allele rs5030737 5219C>T Arg52Cys
B allele rs1800450 5226G>A Gly54Asp
C allele rs1800451 5235G>A Gly57Glu
Y-221X rs7096206 4776C>G
(NG_008196.1)
N.A.
(NP_000233.1)
MASP2 D120G rs72550870 5620A>G
(NG_007289.1) 
Asp120Gly
(NP_006601.2)
Y371D rs12711521 21370T>G
(NG_007289.1)
Tyr371Asp
(NP_006601.2)
FCN2 T236M rs17549193 11369C>T Thr236Met
A258S rs7851696 11434G>T
(NG_011649.1)
Ala258Ser
(NP_004099.2)
TLR2 T-16934A rs4696480 6686T>A N.A.
R753Q rs5743708 25877G>A
(NG_016229.1)
Arg753Gln
(NP_003255.2)
TLR4 D299G rs4986790 13843A>G Asp299Gly
T399I rs4986791 14143C>T
(NG_011475.1)
Thr399Ile
(NP_612564.1)
TLR9 T-1486C rs187084 52261031A>G N.A.
T-1237C rs5743836 52260782A>G
(NC_000003.11)
N.A.
CD14 C-159T rs2569190 5371T>C
(NG_023178.1)
N.A.
NOD2 R702W rs2066844 19877C>T
(NG_008508)
Arg702Trp
(NP_071445.1)
SNP, Single Nucleotide Polymorphism;
Amino acids: Arg (R), Arginine; Asp (D), Asparctic acid; Gln (Q), Glutamine; Gly (G), Glycine; Ile (I), Isoleucine; 
Thr (T), Threonine.
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RESULTS
Patient Demographics
From January 2008 to June 2015 410 patients were included. Of all patients, 307 (75%) 
were male (Table 3). The median age was 47 years (P25-P75 30-60) and the median Injury 
Severity Score (ISS) was 25 (P25-P75 18-29). The trauma mechanism was typically blunt 
(388 patients, 95%), with traffic injuries (206 patients, 50%) and falls from height (120 
patients, 29%) being the most common mechanisms. Of penetrating injuries (22 pa-
tients, 5%) gunshot wounds (9 patients, 2%) and stab wounds (9 patients, 2%) were most 
common. Seventy percent of patients were admitted to the Intensive Care Unit (ICU) and 
stayed there for a median of three days (P25-P75 0-11). The median highest SOFA score 
measured during ICU stay was 8 (P25-P75 5-11) and 220 patients (54%) were mechanically 
ventilated during a median of 141 hours (P25-P75 26-340). A total of 22 (5%) patients died, 
mostly as a result of traumatic brain injury (TBI) (20 of 22; 91%).
Genotype frequencies
Of the 16 SNPs studied the percentage of non-wild type (heterozygous and homozy-
gous variants combined) ranged from 5.4% for MASP2 D120G and 7.3% for TLR2 R753Q 
to 74.4% for TLR2 T-16934A and 75.4% for CD14 C-159T (Table 3). For two SNPs, MBL2 YX 
and MASP2 D120G, no homozygous variant genotypes were found. Apart from MBL2 YX 
(χ2 = 17.68, 1 d.f., p<0.001) and MASP2 Y371D (χ2 = 16.86, 1 d.f., p<0.001), all genotypes 
were in Hardy-Weinberg equilibrium.
For the SNPs in TLR4, the LD r2 value was 0.88 and 0.98 for the American and European 
populations, respectively. The corresponding D’ values were 0.94 and 1.00, respectively. 
In these populations, these SNPs were significantly linked. In African and Asian popula-
tions, no significant linkage was found (r2<0.8).
Effect of individual genotypes on infectious complications
Both in univariate analysis (Table 4) and in multivariable logistic regression analysis 
(Table 5), significantly increased influence of genotype was found for urine culture 
(CD14 C159T TT genotype; Odds Ratio (OR) 2.47; 95% CI 1.13-5.40; p=0.024), wound 
culture (MBL2 exon 1 AO genotype; OR 2.15; 95% CI 1.15-4.01; p=0.016 and FCN2 A258S 
AS genotype; OR 3.05; 95% CI 1.60-5.81; p=0.001 ), SIRS (MASP2 Y371D YD genotype; OR 
1.81; 95% CI 1.08-3.02; p=0.023), septic shock (MASP2 Y371D DD genotype; OR 2.76; 95% 
CI 1.07-7.12; p=0.036 and TLR9 T-1237C TC genotype; OR 2.91; 95% CI 1.54-5.52; p=0.001) 
and mortality (MASP2 Y371D YD genotype; OR 3.98; 95% CI 1.44-10.97; p=0.008 and TLR9 
T-1237C TC genotype; OR 2.83; 95% CI 1.12-7.16; p=0.028). 
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Table 3. Patient, injury, and outcome characteristics
No. of patients*
(n = 410)
PATIENT ChARACTERISTICS
Age (years)† 47 (30-60)
Male gender 307 (74.9%)
INJURY ChARACTERISTICS
Trauma mechanism Traffic accident 206 (50.2%)
Fall from height 120 (29.3%)
Crush injury to thorax or abdomen 20 (4.9%)
Fall from standing height 15 (3.7%)
Gunshot wound 9 (2.2%)
Stabbing 9 (2.2%)
Object against head 8 (2.0%)
Assault 7 (1.7%)
Horseriding accident 5 (1.2%)
Boat accident 5 (1.2%)
Miscellaneous‡ 6 (1.5%)
Blunt trauma 388 (94.6%)
AIS≥1 Head/neck 274 (66.8%)
Face 109 (26.6%)
Thorax 239 (58.3%)
Abdomen 132 (32.2%)
Extremity 212 (51.7%)
External 20 (4.9%)
Injury Severity Score† 25 (18-29)
OUTCOME ChARACTERISTICS
ICU admission 289 (70.5%)
Length of ICU stay (days)† 3 (0-11)
Mechanical ventilation 220 (53.7%)
Duration of mechanical ventilation (hours) † 141 (26-340)
Lactate (mmol/L) <24 hours† 1.3 (0.9-2.3)
Highest level measured during admission† 2.6 (1.7-3.6)
SOFA score First score† 6 (4-8)
Highest score† 8 (5-11)
Positive culture findings Sputum (N=155 patients cultured) 114 (27.8%)
Blood (N=89 patients cultured) 65 (15.9%)
Urine (N=91 patients cultured) 59 (14.4%)
Wound (N=65 patients cultured) 52 (12.7%)
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In multivariable analysis, a reduced risk for developing sepsis was found for TLR2 
R753Q RQ genotype (OR 0.37; 95% CI 0.14-0.98; p=0.046). The univariate effect of CD14 
on mortality could not be confirmed in the multivariable analysis.
Effect of genetic risk score on infectious complications
Table 6 and Figures 1 and 2 show the effects of different genetic risk scores on develop-
ment of infectious complications. In model 1 the effect of already known risk factors age, 
gender, and ISS was tested in a multivariable logistic regression model and plotted in a 
Receiver Operating Curve (ROC; Figures 1 and 2). For all infectious and clinical endpoints 
these risk factors increased the area under the curve (AUC) to well above 0.5 (Table 6). 
These curves were used as baseline reference values to compare two other models in 
which two different approaches were used for computing the genetic risk score.
In model 2 the overall genetic risk score is a summation of one point granted to each 
variant allele found. In this model the influence of all 14 genetic variants studied was 
included. The overall genetic risk score increased the risk of septic shock both when 
entered into the model alone (model 2A; OR 1.26; 95% CI 1.07-1.49; p=0.006) as well as 
in combination with the other known risk factors from model 1 (model 2B; OR 1.25; 95% 
CI 1.06-1.48; p=0.008). The significant effect of the overall genetic risk score on positive 
wound cultures (OR 1.18; 95% CI 1.00-1.69; p=0.049) is lost in Model 2B when combined 
with traditional risk factors (OR 1.18; 95% CI 1.00-1.38). The genetic risk score had no 
significant effect for the other infectious outcomes.
Table 3. Patient, injury, and outcome characteristics (continued)
No. of patients*
(n = 410)
Gram+ (overall) 138 (33.7%)
Gram- (overall) 159 (38.8%)
SIRS <24 hours 283 (69.0%)
Sepsis 140 (34.1%)
Septic shock 51 (12.4%)
Length of hospital stay (days)† 19 (12-33)
Mortality 22 (5.4%)
Time to death (days) † 13 (8-22)
Cause of death: 
 Traumatic brain injury
20 (90.9%)
Arrhythmia 1 (4.5%)
Sepsis 1 (4.5%)
*Data are shown as number (%) unless indicated otherwise; †values are shown as median (P25-P75). ‡In-
cludes explosion, helicopter crash, kite surfing, patient found with neurotrauma due to unknown cause, 
and train accident. ICU, intensive care unit.
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In model 3 only the genetic variants that had an effect in this study were taken into 
account. This data-driven genetic risk score sums the variant alleles only for the SNPs 
with p<0.1 in the multivariable analysis as can be seen in Table 5. Receiver Operating 
Curves for models 1 and 3 are shown in Figure 2. The data-driven genetic risk score alone 
statistically significantly increased the risk of SIRS (OR 1.35; 95% CI 1.08-1.69; p=0.007), 
sepsis (OR 1.33; 95% CI 1.06-1.66; p=0.014), and septic shock (OR 1.37; 95% CI 1.09-1.71; 
p=0.007). This influence is further increased slightly when combined with traditional 
risk factors SIRS (OR 1.42; 95% CI 1.23-1.78; p=0.003), sepsis (OR 1.34; 95% CI 1.06-1.69; 
p=0.014), and septic shock (OR 1.37; 95% CI 1.09-1.72; p=0.007) (model 3B).
DISCUSSION
Identifying trauma patients at risk for developing complications may improve outcome 
and lower the use for hospital resources. Outcome is determined by the magnitude of 
the trauma, the host response, and the medical care that is delivered to the patient. 
The host response to trauma depends on many factors but also seems to depend on 
the genetic integrity of the patient. Of the approximately 25,000 genes in the human 
genome only a few have been studied in human trauma patients and studies are often 
small and unique resulting in limitations to reach conclusions (16). This study aimed to 
evaluate the effects of SNPs at 14 loci in eight genes on seven different chromosomes. 
These innate immune response genes were chosen for their previously reported effects 
on infection in other diseases such as sepsis and liver transplantation (11, 13, 17-20).
Data showed that sequence variations in these innate immune response genes in the 
human genome conferred a risk for adverse outcome after severe trauma. Sequence 
variations in MBL2 exon 1, FCN2 A258S, and CD14 C-159T increased the risk of devel-
oping infectious wound complications and urinary tract infection. MBL2 deficiency is 
known to increase the risk for infections in a number of clinical situations but was never 
studied in a trauma population (21-25). The homozygous variant genotype CD14 C-159T 
TT was associated with increased risk of urinary culture findings in this cohort. MASP2 
A258S has not been intensively studied clinically but in our unique cohort of trauma 
patients variation in this gene increased the risk for wound infections, which is a novel 
finding. Although a role for CD14 was demonstrated in a murine model (26), a clinical 
relation in humans has not yet been established (27).
SIRS, sepsis, septic shock, and even mortality were strongly influenced by individual 
sequence variations in both MASP2 Y371D and TLR9 T-1237C in the present study. The 
MASP2 Y371D DD genotype increased the risk for SIRS, septic shock, and even mortality 
in a multivariable analysis. Carriage of the minor TLR9 T-1237C C allele conferred a risk for 
septic shock and mortality in this cohort. In a small series of orthopedic trauma patients 
Genetic risk score 159
Ta
bl
e 
6:
 E
ffe
ct
 o
f g
en
et
ic
 ri
sk
 s
co
re
 o
f d
iff
er
en
t g
en
ot
yp
es
 w
ith
 c
ul
tu
re
 fi
nd
in
gs
 a
nd
 c
lin
ic
al
 s
yn
dr
om
es
 in
 p
ol
yt
ra
um
at
iz
ed
 p
at
ie
nt
s
Sp
ut
um
Cu
lt
ur
e
Bl
oo
d
Cu
lt
ur
e
U
ri
ne
Cu
lt
ur
e
W
ou
nd
Cu
lt
ur
e
SI
RS
 *
Se
ps
is
 *
Se
pt
ic
Sh
oc
k 
*
M
or
ta
lit
y
M
od
el
 1
A
U
C 
(9
5%
 C
I)
0.
62
 (0
.5
6-
0.
68
)
0.
60
 (0
.5
2-
0.
68
)
0.
62
 (0
.5
4-
0.
69
)
0.
60
 (0
.5
2-
0.
68
)
0.
60
 (0
.5
4-
0.
66
)
0.
65
 (0
.5
9-
0.
71
)
0.
62
 (0
.5
3-
0.
71
)
0.
79
 (0
.7
0-
0.
88
)
M
od
el
 2
A
O
R 
(9
5%
 C
I)
1.
04
 (0
.9
2-
1.
17
)
1.
11
 (0
.9
6-
1.
29
)
1.
02
 (0
.8
7-
1.
19
)
1.
18
 (1
.0
0-
1.
69
)
1.
10
 (0
.9
8-
1.
23
)
1.
09
 (0
.9
7-
1.
22
)
1.
26
 (1
.0
7-
1.
49
)
1.
22
 (0
.9
6-
1.
54
)
A
U
C 
(9
5%
 C
I)
0.
52
 (0
.4
6-
0.
59
)
0.
56
 (0
.4
8-
0.
64
)
0.
50
 (0
.4
2-
0.
59
)
0.
59
 (0
.5
0-
0.
67
)
0.
55
 (0
.4
9-
0.
61
)
0.
55
 (0
.4
9-
0.
61
)
0.
61
 (0
.5
3-
0.
70
)
0.
61
 (0
.7
0-
0.
88
)
M
od
el
 2
B
O
R 
(9
5%
 C
I)
1.
05
 (0
.9
3.
-1
.1
8)
1.
11
 (0
.9
6-
1.
29
)
1.
01
 (0
.8
6-
1.
19
)
1.
18
 (1
.0
0-
1.
38
)
1.
10
 (0
.9
8-
1.
24
)
1.
09
 (0
.9
7-
1.
23
)
1.
25
 (1
.0
6-
1.
48
)
1.
22
 (0
.9
4-
1.
61
)
A
U
C 
(9
5%
 C
I)
0.
62
 (0
.5
6-
0.
68
)
0.
61
 (0
.5
4-
0.
69
)
0.
62
 (0
.5
4-
0.
70
)
0.
63
 (0
.5
5-
0.
71
)
0.
61
 (0
.5
5-
0.
67
)
0.
65
 (0
.6
0-
0.
71
)
0.
65
 (0
.5
7-
0.
73
)
0.
81
 (0
.7
2-
0.
90
)
M
od
el
 3
A
O
R 
(9
5%
 C
I)
1.
19
 (0
.9
1-
1.
54
)
1.
31
 (0
.8
7-
1.
97
)
1.
16
 (0
.9
1-
1.
47
)
1.
18
 (0
.9
4-
1.
48
)
1.
35
 (1
.0
8-
1.
69
)
1.
33
 (1
.0
6-
1.
66
)
1.
37
 (1
.0
9-
1.
71
)
1.
34
 (0
.9
6-
0.
87
)
A
U
C 
(9
5%
 C
I)
0.
53
 (0
.4
8-
0.
61
)
0.
55
 (0
.4
8-
0.
63
)
0.
55
 (0
.4
7-
0.
63
)
0.
57
 (0
.4
8-
0.
65
)
0.
58
 (0
.5
2-
0.
64
)
0.
56
 (0
.5
1-
0.
62
)
0.
60
 (0
.5
1-
0.
69
)
0.
60
 (0
.4
7-
0.
72
)
M
od
el
 3
B
O
R 
(9
5%
 C
I)
1.
25
 (0
.9
5-
1.
63
)
1.
31
 (0
.8
7-
1.
98
)
1.
14
 (0
.8
9-
1.
46
)
1.
18
 (0
.9
4-
1.
48
)
1.
42
 (1
.2
3-
1.
78
)
1.
34
 (1
.0
6-
1.
69
)
1.
37
 (1
.0
9-
1.
72
1.
37
 (0
.9
5-
1.
96
)
A
U
C 
(9
5%
 C
I)
0.
63
 (0
.5
7-
0.
69
)
0.
62
 (0
.5
4-
0.
70
)
0.
63
 (0
.5
5-
0.
71
)
0.
63
 (0
.5
4-
0.
71
)
0.
64
 (0
.5
8-
0.
69
)
0.
66
 (0
.6
0-
0.
71
)
0.
65
 (0
.5
6-
0.
73
)
0.
79
 (0
.6
9-
0.
89
)
M
ul
tiv
ar
ia
bl
e 
lo
gi
st
ic
 re
gr
es
si
on
 m
od
el
s 
w
er
e 
m
ad
e 
fo
r e
ac
h 
in
di
vi
du
al
 o
ut
co
m
e 
m
ea
su
re
 (i
.e
., 
po
si
tiv
e 
cu
ltu
re
 o
r i
nf
ec
tio
us
 c
om
pl
ic
at
io
n)
 a
s 
de
pe
nd
en
t v
ar
ia
bl
e.
 
St
at
is
tic
al
ly
 s
ig
ni
fic
an
t d
at
a 
ar
e 
in
di
ca
te
d 
in
 b
ol
df
ac
e.
* 
SI
RS
, s
ep
si
s, 
an
d 
se
pt
ic
 s
ho
ck
 w
er
e 
on
ly
 d
et
er
m
in
ed
 fo
r p
at
ie
nt
s 
ad
m
itt
ed
 to
 th
e 
In
te
ns
iv
e 
Ca
re
 U
ni
t.
M
od
el
 1
 c
on
ta
in
s 
ag
e,
 g
en
de
r, 
an
d 
IS
S 
as
 c
ov
ar
ia
te
s.
M
od
el
 2
A
 c
on
ta
in
s 
th
e 
ov
er
al
l g
en
et
ic
 ri
sk
 s
co
re
 (i
.e
., 
su
m
 o
f a
ll 
ris
k 
al
le
le
s 
st
ud
ie
d)
 a
s 
co
va
ria
te
.
M
od
el
 2
B 
co
nt
ai
ns
 a
ge
, g
en
de
r, 
IS
S,
 a
nd
 th
e 
ov
er
al
l g
en
et
ic
 ri
sk
 s
co
re
 a
s 
co
va
ria
te
s.
M
od
el
 3
A
 c
on
ta
in
s 
a 
da
ta
-d
riv
en
 g
en
et
ic
 ri
sk
 s
co
re
 (i
.e
., 
su
m
 o
f a
ll 
ris
k 
al
le
le
s 
fo
r S
N
Ps
 w
ith
 a
 p
<0
.1
 in
 th
e 
m
ul
tiv
ar
ia
bl
e 
an
al
ys
is
; s
ee
 T
ab
le
 4
) a
s 
co
va
ria
te
.
M
od
el
 3
B 
co
nt
ai
ns
 a
ge
, g
en
de
r, 
IS
S,
 a
nd
 a
 d
at
a-
dr
iv
en
 g
en
et
ic
 ri
sk
 s
co
re
 a
s 
co
va
ria
te
.
160 Chapter 8
 31
Figure 1. Receiver Operator Characteristic (ROC) plotting the True Positive Rate (Sensitivity) against the 
False Positive Rate (1-Specificity) of the variables studied using the genetic risk score based on literature 
data
The blue line shows the standard risk based on know covariates (model 1). The green line refers to the ge-
netic effect only (model 2A). The red line combines the genetic effect and standard risk (model 2B). 
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 33Figure 2. Receiver Operator Characteristic (ROC) plotting the True Positive Rate (Sensitivity) against the False Positive Rate (1-Specificity) of the variables studied using the genetic risk score based on study data
The blue line shows the standard risk based on know covariates (model 1). The green line refers to the ge-
netic effect only (model 3A). The red line combines the genetic effect and standard risk (model 3B). 
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it was found that patients carrying the TLR9 T-1237C C allele produced higher levels 
of cytokines shortly after trauma (19). Enhanced inflammation in reaction to physical 
injury was proposed to be related to certain genetic polymorphisms in TLR9 (28). Thus, 
it may be that recognition of self-antigens released due to tissue damage might activate 
certain TLR9 variants, which may cause over-secretion of pro-inflammatory cytokines 
(19, 28).
By combining all relevant genes in a genetic risk model it was demonstrated that 
sequence variations in specific genes increase the risk of infectious complications 
in severely injured trauma patients. When compared with the influence of the three 
known risk factors age, gender, and ISS alone our risk model demonstrated that the AUC 
increased for all infectious endpoints indicating a significant effect.
In conclusion, many factors influence outcome of severely injured trauma patients, 
such as the magnitude of the trauma, the host response, and the medical care delivered. 
The host response is, in part, determined by the genetic integrity of the host. Sequence 
variations in selected host immune response genes confer a risk for developing infec-
tious complications. By combining known candidate-gene SNPs in a genetic risk model 
the magnitude of this influence was demonstrated to equal that of other known risk 
factors. By using genome-wide association studies (GWAS) in the future the set of genes 
influencing this risk may even grow larger further improving the genetic risk model. 
With technical innovations reducing duration of GWAS analysis and cost reduction, 
clinical use of this risk model may well be feasible in the near future.  Future research 
will have to focus on enlarging the cohorts of probands, using GWAS and exploring the 
influence of epigenetic factors. 
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IDENTIFYING PATIENTS AT RISk
Identifying trauma patients at risk for developing infectious complications is important. 
It is something clinicians do every day in every hospital in the world. The reliable tools to 
do this are limited. As we have seen in the studies presented in this dissertation studies 
more than half of the patients who are admitted after trauma to an Intensive Care Unit 
(ICU) will develop some pattern of positive culture or infectious complication. These 
infections will increase the length of stay on an ICU department and will use resources 
and produce costs to society. The patient we presented in Chapter two spent a total of 
32 days on the ICU and a total of 76 days in the hospital prior to transfer to a rehabilita-
tion center. If infectious complications could have been foreseen or even prevented it 
would likely have made a considerable difference for the length of hospitalization for 
this patient. Most clinicians will probably recognize this category of patients who, for 
some reason, suffer more than average from infectious complications. Traditionally, 
estimating the risk for developing complications of a severely injured individual patient 
is done by using scoring systems like the Injury Severity Score, and taking into account 
age, gender, co-morbidity, medication, smoking habits, et cetera.
With the possibilities of genotyping and reports of associations between certain 
genotypes and outcomes the question rises if genotyping the trauma patient can be 
advantageous. Do genes exert any effect on outcome in trauma patients? What is known 
already in this field of science? And can genes that possibly predict the occurrence of 
complications be found? Which genes should we look for? And how do we find them? 
Traditionally, candidate gene analysis has been used in sepsis research to identify genes 
that influence outcome. Many of these studies are on sepsis patients only, for example 
patients suffering from pneumosepsis on an ICU. Clearly, associations can be found 
easiest in homogenous study populations, but it is unknown if these effects can also be 
found in real clinical situations such as the heterogeneous trauma population.
PREVENTION OF TRAUMA
Prevention of infectious complications may involve prevention of trauma itself and, 
additionally, improving medical and surgical care. The main causes for global trauma 
mortality are road traffic accidents, falls, suicide, and homicide [1], which, at least to 
certain degrees, may be influenced through road safety regulations, technical improve-
ments in (self-driving) cars, programs for improvement through occupational health 
and safety regulations and other regulations and measures. In medical and surgical care 
prevention of infection could be optimized by hygiene protocols, use of antibiotics, the 
invention of new antibiotics, prevention of multi-drug resistant micro-organisms from 
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contaminating hospitals, and by identification of patients at increased risk for develop-
ing infectious complications.
ThIRD PEAk OF TRUNkEY
Mortality rates were low in our cohort. Patients died only as the result of complications of 
neurotrauma. No patient died as a result of sepsis although many patients actually suf-
fered from sepsis or septic shock. This may on the one hand be a result of improvements 
in modern ICU-treatment which have reached such a quality level that mortality from 
sepsis can be prevented. On the other hand this can be a reflection that the third peak 
of mortality of Trunkey no longer exists in modern hospitals, an observation which has 
been made before [2]. The third peak, however does still exist judging by the amount of 
patients suffering from infectious complications such as septic shock although mortality 
can now be prevented by modern resuscitation techniques, artificial ventilation sup-
port, and the use of antibiotics. However, the increasing numbers of antibiotic resistant 
micro-organisms are a serious threat to global public health and we can only hope that 
this mortality peak will not return in trauma patients in the future.
ThE ROLE OF GENETIC VARIATION
The results of our studies indicate that genomic sequence variations influence outcome 
in severely injured patients to a measurable degree and that this effect can, to some 
extent, be predicted with a genetic risk score model with at least the same reliability 
as it can be predicted with traditional risk factors. By using a candidate-gene approach 
of only a few selected genetic loci in these genetic association studies we were able 
to demonstrate the proof-of-principle of genes being associated with increased rate of 
infections in a very heterogeneous cohort of trauma patients. We also define a specific 
subset of SNPs that may be used in a predictive risk model. This risk model however is 
composed of a relatively small subset of the around 25,000 human genes and its limited 
accuracy renders clinical application at this point premature. The genetic infection risk 
model will first have to be evaluated and probably expanded before it will become a reli-
able tool for clinicians. One way of expanding the subset of sequence variations would 
be by conducting a Genome-Wide Association Study (GWAS) which has not yet been 
done in trauma patients but which has recently produced some new genetic insights 
in ICU patients with pneumosepsis [3]. Both GWAS and candidate-gene analysis tech-
niques have their advantages and disadvantages and reliability of GWAS itself depends 
among other parameters on well defined case and control groups and sufficient sample 
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size. Currently, in the available literature, trauma patient cohorts are small, the largest 
series describing around 600 or 700 patients [4-6]. Moreover, candidate-gene analysis 
and GWAS assume that common genetic variation plays a large role in explaining the 
heritable variation of common disease which actually may only be part of the answer 
since it can be hard to define single molecular functions or certain genes as primary 
causes of specific processes [7]. Genes seem not to be causal agents. Focus is shifting 
towards transcriptome profiling and understanding the influence of epigenetics which 
may also hold clues to the systemic response to trauma or the development of complica-
tions. Epigenetic programming of thousands of genes decides the fate of the organism 
during acute inflammation including sepsis [8]. The transcriptome and epigenome have 
not yet revealed their secrets in populations of sepsis patients or trauma patients. With 
genomics, transcriptomics, and epigenomics combined, the set of variables and spuri-
ous findings is potentially incomprehensibly large. 
Recent technical advances make GWAS an interesting option for further research 
which should lead to the use of specific DNA microarray chips (a ‘Trauma-SNP-chip’) and 
may accurately identify patients at risk for developing complications at the bedside in 
the Emergency Department at reasonably low cost. A similar 70-gene signature test, 
called MammaPrint, is used by breast cancer surgeons to identify those patients who 
may benefit from chemotherapy [9, 10].
The studies presented in this thesis have limitations. Although the volume of the 
cohort studied is at the positive end of all studies published its size has limitations. Also, 
the cohort is heterogeneous in many ways: it consists of multiple ethnicities and it is 
known that genetic variation is strongly related to ethnicity as, for example, is the case 
with MBL2. Ethnicity was not recorded in this study. 
ThERAPEUTIC OPTIONS
What are the options once we have successfully identified a patient at risk for devel-
oping complications? Currently there is no specific treatment available that targets 
sepsis pathophysiology. Until then, one option would be not to offer treatments that 
would further increase the likelihood of complications such as aggressive surgery or 
the use of central venous catheters. One other option would be to prophylactically start 
antimicrobial therapy assuming that the predicted causative organisms are not resistant 
to available antibiotics. Also, substitution of specific proteins rendered unavailable or 
dysfunctional by the genetic variation can be considered. One specific solution could be 
the transfusion of plasma donated by multiple donors of which probably some donors 
contributed without the genetic variation. Also, human plasma-derived proteins can be 
used to substitute the missing or dysfunctional proteins of the patient such as has been 
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studied already in the case of improved opsonofagocytosis following substitution of 
plasma derived MBL in a pediatric population of MBL deficient cancer patients [11, 12]. 
FUTURE PERSPECTIVES
Future studies will have to focus on genomic sequence variations, transcription profiling 
and epigenetics. Enlarging or combining existing cohorts of participating trauma pa-
tients will be another important step. Introducing GWAS to further identify and increase 
the number of relevant SNPs will improve the accuracy of the prediction model. Much 
the same as pharmacogenetics may help in tailoring the choice for the right drug for a 
patient and much the same as the mammaprint SNP-set may guide difficult decisions 
to use chemotherapy, the trauma SNP-set may prove to be of help in personalized 
medicine. Finally, cooperation between all relevant research departments may boost 
research in this expanding largely untrodden field combining genetics, transcription 
profiling and epigenetics ultimately hoping for clues to therapeutically influence sepsis 
pathology following trauma.
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Chapter 1 explains the aims and scope of this thesis. Millions of people die every year 
as a result of injuries. This accounts for 10% of the world’s deaths, 32% more than the 
number of fatalities that result from malaria, tuberculosis, and HIV/AIDS combined. A 
quarter of these deaths are caused by road traffic accidents and one third are the cause 
of violence (homicide, suicide and war casualties). A number of injured patients will die 
at the accident scene or in the first few hours after trauma (the so-called Golden hour). 
But when victims have survived these first few hours and have made it to an Intensive 
Care Unit (ICU) recovery can be compromised by conditions such as Systemic Inflam-
matory Response Syndrome (SIRS), Acute Respiratory Distress Syndrome (ARDS), sepsis, 
septic shock or mortality. Even when death can be prevented, infectious complications 
can give rise to increased morbidity and cost of care. The outcome of trauma is deter-
mined by the severity of the injury, by the quality of medical or surgical care delivered 
and by host factors. Known host risk factors are age, gender and co-morbidity. But it is 
also known that genomic sequence variations can influence the course and outcome 
of a disease. The aim of this thesis was to study the associations between genomic 
sequence variations in severely injured patients and infectious outcome parameters 
during hospital stay.
In Chapter 2 a trauma patient is presented to illustrate the clinical framework of this the-
sis. A 57 year old construction worker tripped over a low brick wall and fell on the back 
of his head from approximately 1 meter height. He was immediately found tetraplegic 
by the paramedics at the scene of trauma as the result of a cord lesion at the level of C3 
and C4. During hospital stay he developed multiple infectious complications caused by 
a number of different micro-organisms. Acute Respiratory Distress Syndrome (ARDS), 
later a pneumonia was treated with a number of antibiotics. During his stay he was also 
diagnosed with tuberculosis. Later, he was treated for pseudomembranous colitis and 
he developed deep venous thrombosis in the right subclavian vein with erysipelas and 
ulceration of the fingers from which multiple micro-organisms were cultured. Urine cul-
tures were positive. This patient appeared to have a number of genomic sequence varia-
tions in important innate immune response genes: AC variant genotype in MBL2 exon 1, 
YX variant genotype in MBL2 promoter region -221, DD homozygous minor allele variant 
genotype in MASP2 Y371D, TM variant genotype in FCN2 T236M, AS variant genotype in 
FCN2 A258S, AA homozygous minor allele variant genotype in TLR2 T-16934A, and CT 
variant genotype in CD14 C159T.
Chapter 3 is a comprehensive review summarizing all genes that have so far been stud-
ied for an effect on infectious complications in cohorts of trauma patients. A total of 44 
SNPs in more than 35 genes have been studied. SNPs in Pattern Recognition Receptors 
(PRR), Signal Transducing Adapter Proteins (STAP), and inflammatory cytokines in the 
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innate immune system are discussed. Different SNPs in TLR 2, TLR4, TLR9, CD14, IL1A, IL1B, 
IL4, IL6, IL10 and TNF are reported to influence SIRS, sepsis or septic shock. Since the 
published studies are often unique and have limited sample sizes, no definitive conclu-
sion can be drawn at this stage.
Chapter 4 discusses the protein Mannose-Binding Lectin (MBL) as well as the MBL2 gene 
that codes for its production on chromosome 10. MBL is a key protein in the Lectin Path-
way, one of the pathway for complement activation together with the classical pathway 
and the alternative pathway. MBL is synthesized in the liver and it circulates in plasma 
in the form of trimers. The Carbohydrate Recognition Domain (CRD) of MBL binds to 
specific ligands present on bacteria, viruses, fungi and protozoa. Following recognition 
of MBL (as a Pattern Recognition Receptor/ PRR) of such a ligand (as a Danger Associated 
Molecular Pattern/ DAMP) it associates with Mannose-Binding Lectin Serine Protease 
(MASP) to activate the complement system. Activation of the complement system ulti-
mately leads to the formation of the Membrane Attack Complex (MAC) that can destroy 
pathogenic micro-organisms.
A number of sequence variations (single nucleotide polymorphism; SNP) are known in 
exon 1, the promoter region and in the 5’-untranslated region (UTR) of MBL2. Three SNPs 
in exon 1 are known for their potential to produce unstable proteins with shorter plasma 
half-lives of MBL. Also the formation of functional oligomers (mainly trimers) is impaired 
in these variant peptides. The normal, wildtype allele is called A and the three variant 
alleles in exon 1 are called B, C, and D respectively. Two polymorphic loci are know in the 
promoter region: -550 (H/L variant) and -221 (Y/X variant). On position +4 in the 5’-UTR 
the P/Q variant can be found. By combination of all these allele variants 7 haplotypes 
can be found in humans (HYPA, LYPA, LYQA, LXPA, HYPD, LYPB, and LYQC) which can be 
associated with high, intermediate or low concentrations of circulating plasma MBL. 
Chapter 5 describes the clinical consequences of such a MBL deficiency. Depending on 
ethnicity sequence variations in MBL2 occur in 1% to 5% of individuals. For example, the 
B-allele is not found in Sub-Saharan West Africa, and the C-allele is not found in Asians 
and American Indians but occurs frequently in Sub-Saharan populations. Heterozygos-
ity occurs in about 30% in most populations. Mutations in MBL2 can reduce circulating 
plasma MBL with 90% depending on haplotype. High worldwide prevalence of MBL 
deficiency or low protein-producing alleles appears to be caused exclusively by human 
migration and genetic drift, indicating that MBL2 variation does not have a strong effect 
on population fitness. However, other data suggest that MBL deficiency may have an 
evolutionary advantage. The diverse role of MBL in innate immunity, particularly its ef-
fects on infectious disease susceptibility, may have led to selection for the heterozygous 
states of MBL2.
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Most people experience no consequences of MBL deficiency because of redundan-
cies in the immune system such as the alternative pathway and classical pathway of 
complement activation. Increased susceptibility to infection is generally seen in patients 
with MBL deficiency when additional factors that compromise the immune system 
are present. It is possible that another part of the immune system that overlaps with 
MBL is functioning at the low end of normal in these individuals, and this lower level 
of function is not sufficient to make up for the MBL deficiency. Low levels of MBL are 
also associated with more severe disease and worse outcomes with certain infections, 
including community-acquired pneumonia, invasive pneumococcal disease, Escherichia 
coli-induced pyelonephritis,  Chlamydia trachomatis  genital tract infections, and hepa-
titis B virus infections. Low MBL levels are associated with increased susceptibility to 
meningococcal disease, tuberculosis, and Legionnaires’ disease; recurrent tonsillitis, 
malaria, and vulvovaginitis; and poor immune response to influenza vaccination. In this 
chapter further associations are discussed between MBL-deficiency and auto-immunity, 
rheumatoid arthritis, systemic lupus erythematodes, celiac disease, ischemia/reperfu-
sion-syndrome, cardiovascular disease, cerebrovascular disease, cancer and trauma.
Mannose-binding lectin (MBL) deficiency is generally defined as a serum level 
<500  ng/mL. It is suggested to perform an evaluation of all arms of the complement 
system (classical, alternative, and lectin pathways) in individuals with recurrent  and/
or  severe respiratory tract infections and in patients immunocompromised for other 
reasons, such as transplantation patients with recurrent infections who have decreased 
cellular immunity due to immunosuppressive drug therapy, since these are the patients 
most likely to benefit from the antibiotic prophylaxis and treatment. Testing includes 
total hemolytic complement (CH50), alternative pathway hemolytic (AH50), and MBL 
assays.
Patients with recurrent infections should be treated similarly to other patients with 
complement deficiencies. This includes prompt treatment with antibiotics with each 
febrile infection and possible prophylactic antibiotics, as is done with patients who are 
postsplenectomy or who have symptomatic immunoglobulin A (IgA) deficiency. In ad-
dition, these patients should receive pneumococcal and meningococcal vaccines, with 
documentation of antibody responses.
Animal studies and phase-I/II human studies suggest that replacement therapy with 
plasma-derived MBL is safe. However, it is still an experimental treatment and not avail-
able commercially. Recombinant human MBL protein (rhMBL), derived from a Chinese 
hamster ovary cell line, is untested and is also not commercially available.
Chapter 6 describes a prospective cohort of 219 severely injured trauma patients 
treated in a Level 1 Trauma Center. All patients were genotyped for a total of 6 SNPs 
in MBL2, FCN2 and MASP2 using high-resolution melting analysis (HRMA). Association 
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of genotype with prevalence of positive culture findings (in urine, wounds, blood and 
sputum) as well as clinical parameters SIRS, sepsis, septic shock and mortality was tested 
by χ2 and logistic regression analysis. More than 50 per cent developed a positive cul-
ture from sputum, wounds, blood or urine. A systemic inflammatory response syndrome 
(SIRS) developed in 64% of patients, sepsis in 36% and septic shock in 17%. Patients 
with a MBL2 exon 1 variant allele were more prone to positive wound cultures. A MASP2 
Y371D DD genotype predisposed to SIRS and septic shock. A FCN2 A258S AS genotype 
predisposed to positive wound cultures and septic shock.
Chapter 7 studies this same prospective cohort of patients who were now genotyped 
for a total of 7 SNPs in TLR2, TLR4, TLR9, and CD14 using HRMA. Association of genotype 
with prevalence of positive culture findings (in urine, wounds, blood and sputum) as 
well as clinical parameters SIRS, sepsis, septic shock and mortality was tested by χ2 
and logistic regression analysis.. More than 50% developed a positive culture finding in 
sputum, wounds, blood, or urine. SIRS developed in 64%, sepsis in 36%, and septic shock 
in 17%. The TLR2 T-16934A TA genotype increased the risk of a Gram-positive infection 
and SIRS. Trends were noted for TLR9 and CD14 but did not reach statistical significance. 
Sepsis and septic shock were unrelated to any of the SNPs studied.
Chapter 8 describes a prospective cohort of 410 severely injured trauma patients in 
whom a total of 16 SNPs in eight immune reponse genes (MBL2, MASP2, FCN2, TLR2, TLR4, 
TLR9, CD14 en NOD2) on seven different chromosomes were studied for associations 
with infectious complications. Mean ISS was 25 and most patients (95%) sustained blunt 
trauma of which road traffic accidents (50%) and falls from height (29%) were the most 
common trauma mechanisms. A total of 70% of patients were admitted to an ICU. The 
median highest SOFA score was 8 points. More than 50% of patients needed mechanical 
ventilation for a median duration of 141 hours. In univariate and multivariable analysis 
statistically significant positive associations were found for individual genotypes for 
urine culture (CD14 C159T TT genotype), wound culture (MBL2 exon 1 AO genotype and 
FCN2 A258S AS genotype), SIRS (MASP2 Y371D YD genotype), septic shock (MASP2 Y371D 
DD genotype and TLR9 T-1237C TC genotype) and mortality (MASP2 Y371D YD genotype 
and TLR9 T-1237C TC genotype). Then, different genetic risk score models were tested 
in a multivariable logistic regression analysis and plotted in a receiver operator curve 
(ROC). It was shown that the genetic risk score model that was composed of clinically 
relevant genes is able to predict SIRS, sepsis and septic shock as accurate as the use of 
traditional risk factors age, gender and ISS.
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In hoofdstuk 1 is het doel van dit proefschrift uiteengezet. Miljoenen mensen sterven 
jaarlijks wereldwijd aan de gevolgen van trauma. Een kwart van die sterfgevallen ontsta-
at in het verkeer en een derde door geweld (moord, zelfmoord en oorlogsslachtoffers). 
Een deel van de slachtoffers overlijdt ter plaatse van het ongeval of binnen enkele uren 
(Golden hour). Wanneer slachtoffers de eerste uren hebben overleefd en een Intensive 
Care Unit (ICU) hebben weten te bereiken kan het beloop gecompliceerd raken door 
onder meer Systemic Inflammatory Response Syndrome (SIRS), Acute Respiratory Dis-
tress Syndrome (ARDS), sepsis, septische shock of overlijden. Ook als het overlijden kan 
worden afgewend zorgen infectieuze complicaties voor veel morbiditeit en zorgkosten. 
De uitkomst van trauma wordt bepaald door de ernst van het trauma, factoren in de 
patiënt en door de geleverde medische zorg. Bekende risicofactoren van de patiënt 
zijn leeftijd, geslacht en comorbiditeit. Ook is bekend dat variatie in het genoom van 
de patiënt invloed kan hebben op de uitkomst van vele ziekten. In dit proefschrift is 
onderzocht of genetische variatie bij ernstig gewonde traumapatiënten de infectieuze 
uitkomst gedurende de ziekenhuisopname beïnvloedt.
In hoofdstuk 2 wordt het klinisch kader van de vraagstelling in dit proefschrift geïl-
lustreerd aan de hand van een casus van een traumapatiënt. Een 57-jarige bouwvakker 
struikelde over een muurtje en viel ongeveer 1 meter achterover op zijn hoofd. Hij was 
meteen tetraplegisch ten gevolge van een laesie in het ruggenmerg op niveau C3 en C4. 
Tijdens de opname ontwikkelde patiënt Acute Respiratory Distress Syndrome (ARDS) 
en een pneumonie  waarvoor hij met meerdere antibiotica werd behandeld. Er werd 
tuberculose vastgesteld en een pseudomembraneuze colitis werd behandeld. Ook 
ontwikkelde hij een diep veneuze thrombose in de rechter vena subclavia met erysip-
elas en ulceratie van de vingers waarin meerdere micro-organismen werden gekweekt. 
De urinekweek was ook positief.
Bij analyse bleek deze patiënt verschillende mutaties te hebben in belangrijke im-
muunresponsgenen, genen in het aangeboren immuunsysteem: AC genotype in MBL2 
exon 1, YX genotype in MBL2 promoter regio -221, homozygoot variant genotype DD in 
MASP2 Y371D, heterozygoot genotype TM in FCN2 T236M, heterozygoot genotype AS 
in FCN2 A258S, homozygoot variant genotype AA in TLR2 T-16934A en heterozygoot 
genotype CT in CD14 C-159T.
In hoofdstuk 3 is onderzocht welke genen tot nog toe onderzocht zijn op een effect 
op infectieuze complicaties in populaties van traumapatiënten. Uit een diepgaande 
literatuurstudie blijkt dat SNPs in meer dan 35 genen onderzocht zijn. De Pattern Rec-
ognition Receptors (PRR), Signal Transducing Adapter Proteins (STAP) en Inflammatory 
Cytokines van het aangeboren immuunsysteem worden besproken. Het blijkt dat de 
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verschillende studies vaak uniek zijn en niet zelden kleine patiëntenaantallen hebben 
zodat vooralsnog geen eenduidige conclusies kunnen worden getrokken.
In hoofdstuk 4 wordt het eiwit Mannose-Binding Lectin (MBL) besproken evenals MBL2, 
het gen op chromosoom 10 dat codeert voor de productie van MBL. MBL is onderdeel 
van het Lectine pad, een van de drie bekende paden om het complementsysteem te 
activeren. Er zijn genetische variaties (Single Nucleotide Polymorphism; SNP) bekend 
in exon 1, de promoter regio en de de 5’-UTR (untranslated region) van MBL2. In exon 
1 van MBL2 zijn drie SNPs bekend die leiden tot productie van instabiele eiwitten met 
een kortere plasma halfwaardetijd van MBL. Bovendien lijkt de vorming van functionele 
oligomeren door deze variante eiwitten verstoord. Het normale allel wordt A genoemd 
en de drie variante allelen respectievelijk B, C en D. In de promoter regio bestaan eve-
neens meerdere polymorfe loci: -550 (H/L variant), -221 (Y/X variant) en in de 5’-UTR op 
positie +4 (P/Q variant). Aldus zijn door combinatie zeven haplotypen bekend bij de 
mens (HYPA, LYPA, LYQA, LXPA, HYPD, LYPB, en LYQC) die geassocieerd zijn met hoge, 
intermediaire of lage concentraties van circulerend MBL. MBL wordt gesynthetiseerd in 
de lever en circuleert in plasma in de vorm van trimeren. Het CRD (Carbohydrate Recog-
nition Domain) van MBL bindt aan specifieke koolhydraten die voorkomen op bacteriën, 
virussen, schimmels en protozoa. Na herkenning van MBL (als Pattern Recognition 
Receptor - PRR) van een van dergelijke koolhydraten (als Danger Associated Molecular 
Pattern - DAMP) ontstaat, na associatie met MASP (Mannose-Binding Associated Serine 
Protease), activatie van het complement systeem dat uiteindelijk leidt tot productie van 
het MAC (Membrane Attack Complex) dat verdere destructie van het pathogene micro-
organisme tot gevolg heeft.
In hoofdstuk 5 worden de klinische gevolgen beschreven van MBL-deficiëntie. Afhan-
kelijk van etniciteit komen MBL2 mutaties voor bij 1% tot 65% van de individuen. Het 
B-allel komt bijvoorbeeld niet voor in sub-Sahara West-Afrika. Het C-allel daarentegen 
komt niet voor in Aziaten en Amerikaanse Indianen maar komt veel voor in sub-Sahara 
populaties. Heterozygotie komt in ongeveer 30% voor in de meeste populaties. Mutaties 
kunnen het circulerend MBL in plasma met 90% verlagen afhankelijk van het haplotype. 
Het algemeen voorkomen van MBL deficiëntie op aarde lijkt voornamelijk door migratie 
en genetic drift te zijn veroorzaakt hetgeen erop wijst dat MBL2 variatie niet veel invloed 
heeft op de fitness van een populatie. De pluriforme rol van MBL in het aangeboren 
immuunsysteem heeft mogelijk geleid tot de hoge frequentie van heterozygotie en 
daarom wordt ook wel beweerd dat hierdoor een selectievoordeel heeft kunnen ont-
staan.
De meeste mensen ondervinden geen gevolgen van een MBL-deficiëntie vanwege de 
aanwezigheid van alternatieve routes om het aangeboren immuunsysteem te activeren 
Samenvatting 189
zoals de zogenaamde klassieke route en de alternatieve route. Wanneer andere factoren 
de beschikbaarheid van immuunpotentieel bedreigen kunnen symptomen ontstaan zo-
als wanneer het verworven immuunsysteem eveneens gecompromitteerd is en er vat-
baarheid ontstaat voor bacteriële infecties, voornamelijk door ingekapselde bacteriën.
De ernst van bepaalde infecties lijkt toegenomen in geval van MBL-deficiëntie zoals 
bij community aquired pneumonie, infectie met pneumococcen, pyelonefritis door E. 
coli en de kans op occlusie van de tuba fallopii door Chlamydia. Maar ook lijkt juist de 
vatbaarheid voor bepaalde infecties verhoogd zoals onder meer het geval is bij menin-
gococcen, tuberculose, legionella en lepra.
In dit hoofdstuk worden verdere associaties besproken tussen MBL-deficiëntie en 
auto-immuniteit, rheumatoide arthritis, systemische lupus erythematodes, coeliakie, 
ischemie/reperfusie-syndroom, cardiovasculaire aandoeningen, cerebrovasculaire 
aandoeningen, kanker en trauma.
De diagnose ‘MBL-deficiëntie’ wordt gesteld als serumwaarden dalen onder 500 ng/
ml. Geadviseerd wordt om alle paden van het complementsysteem te testen (klass-
iek, alternatief en lectine) bij patiënten met recidiverende luchtweginfecties en bij 
patiënten bij wie de cellulaire immuniteit onderdrukt wordt met immunosuppressiva, 
zoals transplantatiepatiënten met recidiverende infecties, omdat deze patiënten meest 
waarschijnlijk baat hebben bij een therapie. CH50, AH50 en serum MBL kunnen worden 
bepaald. 
De behandeling bestaat uit het snel starten met antibiotische therapie bij eerste 
tekenen van symptomen zoals bij de behandeling van andere complement-deficiënties. 
Ook kan substitutie van het MBL eiwit worden overwogen. Dit eiwit wordt gewonnen 
uit humaan plasma maar recombinant humaan MBL (rhMBL) is ook in een ovariële 
cellijn van hamsters geproduceerd. Toediening is veilig gebleken en in vroege studies 
bij neonaten lijkt éénmalige substitutie te leiden tot een fysiologische plasmawaarde 
gedurende drie dagen.
hoofdstuk 6 beschrijft een prospectief cohort van 219 ernstig gewonde patiënten die 
in een Level 1 traumacentrum zijn behandeld. Bij al deze patiënten zijn de genotypes 
bepaald voor MBL2, FCN2 en MASP2. Er werd gezocht naar associaties tussen de respec-
tievelijke genotypen en het ontstaan van infectieuze complicaties. Meer dan 50% van 
de patiënten ontwikkelde een positieve kweek in sputum, bloed, urine of wond. Zo’n 
63% van patiënten ontwikkelde een SIRS, 36% een sepsis en 17% een septische shock. 
Patiënten met een variant allel in MBL2 exon 1 hadden meer kans op een positieve won-
dkweek. Het genotype MASP2 Y371D DD gaf een verhoogde kans op SIRS en septische 
shock. FCN2 A258S AS verhoogde de kans op positieve wondkweken en op septische 
shock. 
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In hoofdstuk 7 wordt in hetzelfde prospectieve cohort van 219 ernstig gewonde 
patiënten gekeken naar associaties tussen SNPs in TLR2, TLR4, TLR9, CD14 en de kans 
op het ontstaan van infectieuze complicaties. Het Toll-like Receptor (TLR) pathway 
speelt een belangrijke rol in het aangeboren afweersysteem en herkent meerdere 
pathogen-associated molecular patterns (PAMPs) op bacteriën, schimmels, virussen en 
protozoa. CD14 is een centraal pattern recognition receptor (PRR) in het aangeboren 
afweersysteem en heeft interactie met TLR als co-receptor voor de detectie van verschil-
lende PAMPs. Het bleek dat TLR2 T-16934A TA genotype de kans op het ontstaan van 
een gram-positieve infectie vergrootte evenals op SIRS. Voor TLR4, TLR9 en CD14 werden 
geen statistisch significante associaties gevonden.
In hoofdstuk 8 wordt een prospectief cohort van 410 ernstig gewonde patiënten 
beschreven bij wie in totaal 16 SNPs in 8 immune respone genes (MBL2, MASP2, FCN2, 
TLR2, TLR4, TLR9, CD14 en NOD2) op 7 verschillende chromosomen worden onderzocht 
op associaties met infectieuze complicaties. De mediane ISS was 25 en de meeste (95%) 
patiënten maakten stomp trauma door waarvan verkeersongevallen (50%) en een val 
van hoogte (29%) de meest voorkomende traumamechanismen waren. In totaal werd 
70% van de patiënten opgenomen op een ICU waar de mediane hoogste SOFA score 8 
bedroeg. Meer dan 50% van de patiënten werd beademd voor een mediane duur van 
141 uur. In univariate en multivariate analyse werden statistisch significante associaties 
van individuele genotypes gevonden voor urinekweek (CD14 C159T TT genotype), won-
dkweek (MBL2 exon 1 AO genotype en FCN2 A258S AS genotype), SIRS (MASP2 Y371D YD 
genotype), septische shock (MASP2 Y371D DD genotype en TLR9 T-1237C TC genotype) 
en mortaliteit (MASP2 Y371D YD genotype en TLR9 T-1237C TC genotype). Vervolgens 
werden verschillende modellen van genetische risicoscore onderzocht, in een multi-
variabele logistische regressie-analyse en geplot in een receiver operator curve (ROC), 
op een voorspellende waarde voor het ontwikkelen van infectieuze complicaties. Het 
blijkt dat deze genetische risicoscore een voorspellende waarde heeft voor SIRS, sepsis 
en septische shock die juist groter is dan de voorspellende waarde van de traditionele 
risicofactoren leeftijd, geslacht en ISS.
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SUMMARY OF PhD TRAINING AND TEAChING
Name PhD Candidate: M.W.G.A. Bronkhorst
Erasmus MC Department: Surgery
Promotor: Prof. Dr. P. Patka
Supervisor: Dr. E.M.M. van Lieshout
1. PhD training
Year Workload (hours/ECTS)
General courses 
- ATLS Generic Instructor Course
- Teach the Teacher
2011
2015
1
1
Specific courses (e.g. Research school, Medical Training)
- Basiscursus Stralingsbescherming 2010 2
Presentations
- EBJIS Heidelberg (D)
- DKOU Berlin (D)
- AAST Boston (USA)
- ECTES Milano (I)
2010
2010
2010
2011
1
1
1
1
(Inter)national conferences
- Traumadagen
- Chirurgendagen
- ECTES Budapest (H)
- ECTES Brussel (B)
- ECTES Frankfurt (D)
2008-2016
2008-2016
2008
2010
2014
6
6
1
1
1
2. Teaching
Year Workload (hours/ECTS)
Lecturing
- AO National Faculty Amsterdam (NL)
- AO National Faculty Sint Michielsgestel (NL)
- AO National Faculty Leiden (NL)
2013
2014
2015
1
1
1
Supervising practicals and excursions, Tutoring
- ATLS Instructor
- AO Table Instructor Davos (CH)/ Oisterwijk (NL)
2011-2016
2010-2011
4
2
Supervising Master’s theses
M.A.Z. Lomax
N. Ruiter
N.D.A. Boye
L.M. Rietveld
2010
2010
2011
2011
2
2
2
2

